[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 570
1. Honig A, Weidler C, Häusler S, Krockenberger M, Buchholz S, Köster F, Segerer SE, Dietl J, Engel JB: Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer. Anticancer Res; 2010 May;30(5):1559-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of polycomb protein BMI-1 in human specimens of breast, ovarian, endometrial and cervical cancer.
  • The current study investigated the expression of BMI-I in human specimens of breast, ovarian, endometrial and cervical cancer.
  • BMI-I expression in human specimens of breast, endometrial and cervical cancer was evaluated by IHC and then compared with the respective benign tissues.
  • RESULTS: BMI-I was significantly (p<0.05) overexpressed in human breast, ovarian, endometrial and cervical cancer specimens as compared to benign controls.
  • In human breast cancer samples, BMI-I expression was most pronounced in the invasion front of the tumour.
  • [MeSH-major] Breast Neoplasms / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Nuclear Proteins / biosynthesis. Nuclear Proteins / physiology. Ovarian Neoplasms / metabolism. Proto-Oncogene Proteins / biosynthesis. Proto-Oncogene Proteins / physiology. Repressor Proteins / biosynthesis. Repressor Proteins / physiology. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Cell Differentiation. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / biosynthesis. Neoplasm Proteins / metabolism. Phenotype. Polycomb Repressive Complex 1


2. Zalinski S, Goumard C, Scatton O, Terris B, Plantier F, Dupin N, Soubrane O: Liver recurrence of a subcutaneous temporal hemangiopericytoma: the index case. J Gastrointest Surg; 2009 Jun;13(6):1155-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hemangiopericytoma is an uncommon soft tissue vascular neoplasm.
  • Its natural history is mostly benign, but recurrences may occur and determining if these late-discovered tumors are distant metastases or synchronous slow and silent-growing locations is sometimes challenging.
  • The histopathological diagnosis and definition of hemangiopericytoma is based on its distinction with solitary fibrous tumors.
  • [MeSH-minor] Breast Neoplasms / pathology. Female. Hepatectomy. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Surg. 1991 Jul;21(4):462-5 [1960907.001]
  • [Cites] Cancer Imaging. 2006 Jun 08;6:56-9 [16766270.001]
  • [Cites] Cancer. 1999 Aug 25;87(4):190-5 [10455206.001]
  • [Cites] Hum Pathol. 1976 Jan;7(1):61-82 [1244311.001]
  • [Cites] Histopathology. 2006 Jan;48(1):63-74 [16359538.001]
  • [Cites] Acta Cytol. 2003 Mar-Apr;47(2):281-6 [12685202.001]
  • [Cites] Semin Diagn Pathol. 1995 Aug;12(3):221-32 [8545589.001]
  • [Cites] J Ultrasound Med. 2008 Apr;27(4):667-71 [18359915.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 Jun;29(6):409-11 [17551404.001]
  • [Cites] Hum Pathol. 1998 Jun;29(6):636-40 [9635686.001]
  • [Cites] Cancer. 1975 Dec;36(6):2232-44 [1203874.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1413-8 [15668900.001]
  • [Cites] Ann Surg. 2006 Dec;244(6):897-907; discussion 907-8 [17122615.001]
  • [Cites] Transplantation. 1999 Feb 15;67(3):488-9 [10030302.001]
  • [Cites] World J Gastroenterol. 2005 Jul 21;11(27):4281-4 [16015707.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Ann Surg. 1942 Jul;116(1):26-33 [17858068.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Apr;28(4):237-40 [16679922.001]
  • [Cites] J Am Coll Surg. 2003 Oct;197(4):687-8 [14522337.001]
  • [Cites] Ann Surg Oncol. 1998 Jun;5(4):350-5 [9641457.001]
  • [Cites] Am J Otolaryngol. 2000 Jul-Aug;21(4):238-43 [10937909.001]
  • [Cites] Neurosurgery. 1989 Oct;25(4):514-22 [2797389.001]
  • [Cites] Aust N Z J Med. 1991 Dec;21(6):884-5 [1818550.001]
  • [Cites] Cancer. 1999 May 15;85(10):2245-8 [10326704.001]
  • [Cites] Prog Urol. 2003 Jun;13(3):498-501 [12940206.001]
  • [Cites] Surg Today. 1993;23(7):644-8 [8369618.001]
  • [Cites] Ann Surg. 1960 Nov;152:804-8 [13716736.001]
  • (PMID = 19148704.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Abd El-Wahed MM: Expression and subcellular localization of maspin in human ovarian epithelial neoplasms: correlation with clinicopathologic features. J Egypt Natl Canc Inst; 2005 Sep;17(3):173-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Maspin is an inhibitor of serine proteinases with tumor suppressor activity that is down-regulated in breast and prostate cancer, but overexpressed in pancreatic carcinoma.
  • They included 18 benign, 14 low malignant potential (LMP) and 46 malignant epithelial ovarian neoplasms, in addition to seven specimens from normal ovarian tissues as a control.
  • RESULTS: Immunohistochemical study of maspin expression using streptavidin biotin immunoperoxidase method revealed that, normal ovarian surface epithelium did not express maspin as well as benign serous and mucinous ovarian epithelial neoplasm.
  • However, all benign Brenner ovarian tumors were maspin positive.
  • These results may offer new insights regarding the role of maspin in ovarian cancer that may also impact diagnosis and treatment strategies.
  • Moreover, variation in maspin expression between Brenner tumor and other epithelial surface ovarian tumors may indicate that the different histological types probably represent distinct disease entities and involve different molecular pathways.
  • [MeSH-minor] Adolescent. Adult. Brenner Tumor / metabolism. Brenner Tumor / pathology. CA-125 Antigen / analysis. Carcinoembryonic Antigen / analysis. Epithelium / metabolism. Female. Genes, Tumor Suppressor. Humans. Immunohistochemistry. Middle Aged. Ovary / metabolism. Serpins

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16799655.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / SERPIN-B5; 0 / Serine Proteinase Inhibitors; 0 / Serpins
  •  go-up   go-down


Advertisement
4. Burkholder HC, Witherspoon LE, Burns RP, Horn JS, Biderman MD: Breast surgery techniques: preoperative bracketing wire localization by surgeons. Am Surg; 2007 Jun;73(6):574-8; discussion 578-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast surgery techniques: preoperative bracketing wire localization by surgeons.
  • With the development of expertise in image guidance for breast surgery, many surgeons now perform preoperative wire localization themselves.
  • Use of a single wire versus multiple wires to bracket a radiographic breast abnormality has previously been described, although benefits of this technique based on clinical outcomes such as margin status, tissue volume removed, and re-excision rates have not been established.
  • This study is a retrospective analysis of wire-localized breast biopsies performed by 14 surgeons over 29 months; stereotactic and ultrasound guidance were used.
  • After controlling for tumor node metastases stage, single and multiple wire placements were compared using endpoints of margin status, need for re-excision, and total volume of tissue removed.
  • Use of more than one localizing wire was associated with greater volume of tissue removal (measured in centimeters cubed) in benign disease (46 vs 25, P < 0.001), equivalent volumes in stage 0 disease (73 vs 67), less volume in stage 1 disease (113 vs 164), and less volume in stages 2 through 4 (158 vs 207, P = 0.03).
  • Outcomes based on surgeon case volume during the study period demonstrated that low- (1-40), medium- (41-80), and high-volume (>80) surgeons did not differ in the type or stage of breast pathology treated.
  • Surgeons with high case volumes were more likely to place multiple localizing wires (P < 0.001) and were more likely to do a breast-conserving procedure if re-excision was performed (P < 0.018).
  • Surgeon experience has a positive impact on quality outcome measures such as performance of a definitive procedure at the time of initial surgery and use of breast-conserving procedures at the time of re-excision.
  • Multiple wire localization can be used to significantly reduce the volume of breast tissue removed in malignant disease without sacrificing margin status or increasing the need for future re-excision.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy / instrumentation. Stereotaxic Techniques / instrumentation
  • [MeSH-minor] Biopsy / instrumentation. Breast / pathology. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Carcinoma, Lobular / pathology. Carcinoma, Lobular / surgery. Female. Humans. Lymphatic Metastasis / pathology. Mastectomy, Segmental / instrumentation. Neoplasm Staging. Precancerous Conditions / pathology. Precancerous Conditions / surgery. Reoperation. Retrospective Studies. Surgery, Computer-Assisted / instrumentation. Treatment Outcome. Ultrasonography, Interventional / instrumentation

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658094.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Stojadinovic A, Hooke JA, Shriver CD, Nissan A, Kovatich AJ, Kao TC, Ponniah S, Peoples GE, Moroni M: HYOU1/Orp150 expression in breast cancer. Med Sci Monit; 2007 Nov;13(11):BR231-239
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HYOU1/Orp150 expression in breast cancer.
  • Preliminary studies demonstrated increased HYOU1/Orp150 expression in prostate, bladder and invasive breast cancer.
  • This study further evaluates HYOU1/Orp150 expression in different stages of breast cancer such as benign, pre-malignant and malignant lesions, and correlates it with clinical and pathological data.
  • MATERIAL/METHODS: Sixty-six paraffin-embedded breast tissue sections were stained by immunohistochemistry using HYOU1/Orp150 antibody.
  • RESULTS: There was a small but significant increase (P<0.01) in HYOU1/Orp150 expression as the tumor transformed from benign (mean 1.52+/-0.12) to ductal carcinoma in situ (mean 2.05+/-0.14) and invasive carcinoma (mean 2.1+/-0.17).
  • HYOU1/Orp150 was partially lost in the benign tissue adjacent to purely invasive cancer (0.88+/-0.22) and it was less (P=0.046) than what was found in benign only lesions (1.52+/-0.12) or in benign components adjacent to DCIS (1.47+/-0.16).
  • Overexpression of HYOU1/Orp150 was associated with tumor lymph node involvement, presence of lymphovascular invasion, and absence of estrogen receptor expression (P<0.01).
  • CONCLUSIONS: HYOU1/Orp150 is overexpressed in some invasive breast cancers and its overexpression appears to be associated with indicators of poor prognosis.
  • [MeSH-major] Breast Neoplasms / metabolism. Proteins / metabolism
  • [MeSH-minor] Breast Diseases / metabolism. Carcinoma, Intraductal, Noninfiltrating / metabolism. Female. HSP70 Heat-Shock Proteins. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies


6. Zafrakas M, Losen I, Knüchel R, Dahl E: Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue. BMC Cancer; 2008;8:145
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancer of the rudimentary gene homologue (ERH) expression pattern in sporadic human breast cancer and normal breast tissue.
  • BACKGROUND: The human gene ERH (Enhancer of the Rudimentary gene Homologue) has previously been identified by in silico analysis of four million ESTs as a gene differentially expressed in breast cancer.
  • The aim of the present study was a systematic characterization of ERH expression in human breast cancer in order to evaluate possible clinical applications of this molecule.
  • METHODS: The expression pattern of ERH was analyzed using multiple tissue northern blots (MTN) on a panel of 16 normal human tissues and two sets of malignant/normal breast and ovarian tissue samples.
  • ERH expression was further analyzed in breast cancer and normal breast tissues and in tumorigenic as well as non-tumorigenic breast cancer cell lines, using quantitative RT-PCR and non-radioisotopic in situ hybridization (ISH).
  • In the two MTN sets of malignant/normal breast and ovarian tissue,ERH was clearly more abundantly expressed in all tumours than in normal tissue samples.
  • Quantitative RT-PCR analyses showed that ERH expression was significantly more abundant in tumorigenic than in non-tumorigenic breast cancer cell lines (4.5-fold; p = 0.05, two-tailed Mann-Whitney U-test); the same trend was noted in a set of 25 primary invasive breast cancers and 16 normal breast tissue samples (2.5-fold; p = 0.1).
  • These findings were further confirmed by non-radioisotopic ISH in human breast cancer and normal breast tissue.
  • CONCLUSION: ERH expression is clearly up-regulated in malignant as compared with benign breast cells both in primary human breast cancer and in cell models of breast cancer.
  • Further studies on large breast cancer tissue cohorts should determine whether ERH could function as a prognostic factor or even a drug target in the treatment of human breast cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Breast / metabolism. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Cell Cycle Proteins / biosynthesis. Gene Expression Regulation, Neoplastic / physiology. Neoplasm Proteins / biosynthesis. Transcription Factors / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Line, Tumor. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biol Chem. 2001 Sep;382(9):1379-85 [11688721.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):266-73 [17698176.001]
  • [Cites] Int J Oncol. 2004 Sep;25(3):641-9 [15289865.001]
  • [Cites] Genetics. 1994 Dec;138(4):1163-70 [7896098.001]
  • [Cites] Genomics. 1996 Feb 15;32(1):125-7 [8786099.001]
  • [Cites] Gene. 1997 Feb 28;186(2):189-95 [9074495.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4251-60 [10518618.001]
  • [Cites] J Pathol. 2005 Jan;205(1):21-8 [15586368.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):683-9 [15670829.001]
  • [Cites] Biochemistry. 2005 Apr 5;44(13):5017-23 [15794639.001]
  • [Cites] FEBS J. 2008 Jan;275(2):332-40 [18081865.001]
  • [Cites] Oncogene. 2008 Jan 31;27(6):865-76 [17653090.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1453-9 [16187283.001]
  • [Cites] Acta Crystallogr Sect F Struct Biol Cryst Commun. 2005 May 1;61(Pt 5):531-3 [16511088.001]
  • [Cites] FEBS J. 2006 Oct;273(20):4728-41 [16984396.001]
  • [Cites] Mol Cell. 2003 Apr;11(4):1055-66 [12718890.001]
  • (PMID = 18500978.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / ERH protein, human; 0 / Neoplasm Proteins; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2426700
  •  go-up   go-down


7. El-Attar HA, Ragab MS, Sheta MI, Ahmed AS: Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers. Asian Pac J Cancer Prev; 2010;11(4):893-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocyte growth factor in Egyptian females with breast benign lumps and cancers.
  • BACKGROUND: Hepatocyte growth factor (HGF) also known as scatter factor (SF) and its receptor c-met play important roles in mammary differentiation and have been implicated in mammary carcinogenesis.
  • OBJECTIVE: Estimation of the plasma level of HGF in females with benign breast lumps or breast carcinomas and correlating levels with important prognostic parameters.
  • SUBJECTS: Sixty eight adult premenopausal females were divided into control group of fifteen healthy volunteers and fifty-three patients subdivided into fifteen with benign breast lumps and thirty-eight with breast carcinomas.
  • METHODS: A thorough clinical examination, plain chest x-rays, ultrasonography of the abdomen and pelvis, pre- operative fine needle aspiration cytology, estimation of fasting serum glucose, urea, creatinine and uric acid levels, alanine aminotransferase activities, C-reactive protein, HGF level and histopathological examination of the breast masses were performed.
  • RESULTS: Significant increase in HGF levels was found in patients with benign breast lumps and in breast cancer patients when each was compared to controls and when cancer patients were compared to the benign breast lumps group.
  • CONCLUSION: The serum level of HGF is an independent prognostic indicator for breast cancer.
  • [MeSH-major] Breast Neoplasms / blood. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / blood. Carcinoma, Ductal, Breast / pathology. Fibroadenoma / blood. Hepatocyte Growth Factor / blood
  • [MeSH-minor] Age Factors. Egypt. Female. Fibrocystic Breast Disease / blood. Humans. Inflammation / blood. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Burden


8. Wu ZS, Wu Q, Wang CQ, Wang XN, Wang Y, Zhao JJ, Mao SS, Zhang GH, Zhang N, Xu XC: MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis. BMC Cancer; 2010 Oct 09;10:542
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MiR-339-5p inhibits breast cancer cell migration and invasion in vitro and may be a potential biomarker for breast cancer prognosis.
  • Detection of their expression may lead to identifying novel markers for breast cancer.
  • METHODS: We profiled miRNA expression in three breast cancer cell lines (MCF-7, MDA-MB-231, and MDA-MB-468) and then focused on one miRNA, miR-339-5p, for its role in regulation of tumor cell growth, migration, and invasion and target gene expression.
  • We then analyzed miR-339-5p expression in benign and cancerous breast tissue specimens.
  • Real-time PCR indicated that miR-339-5p expression was downregulated in the aggressive cell lines MDA-MB-468 and MDA-MB-231 and in breast cancer tissues compared with benign tissues.
  • Transfection of miR-339-5p oligonucleotides reduced cancer cell growth only slightly but significantly decreased tumor cell migration and invasion capacity compared with controls.
  • Cox proportional hazards analyses showed that miR-339-5p expression was an independent prognostic factor for breast cancer patients.
  • CONCLUSIONS: MiR-339-5p may play an important role in breast cancer progression, suggesting that miR-339-5p should be further evaluated as a biomarker for predicting the survival of breast cancer patients.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Int J Cancer. 2011 Jan 1;128(1):132-43 [20309880.001]
  • [Cites] Semin Cancer Biol. 2003 Aug;13(4):253-8 [14563119.001]
  • [Cites] Oncogene. 2003 Dec 4;22(55):8948-51 [14654791.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Jun 18;247(2):357-60 [9642131.001]
  • [Cites] Nature. 2004 Dec 2;432(7017):635-9 [15577913.001]
  • [Cites] Nat Med. 2004 Dec;10(12):1329-35 [15531890.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Nat Genet. 2005 May;37(5):495-500 [15806104.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3509-12 [15867338.001]
  • [Cites] Cell. 2005 Jul 15;122(1):6-7 [16009126.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1179-84 [16096373.001]
  • [Cites] Development. 2005 Nov;132(21):4653-62 [16224045.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]
  • [Cites] Neoplasia. 2006 Apr;8(4):290-301 [16756721.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1519-29 [16671089.001]
  • [Cites] J Biol Chem. 2007 Jan 12;282(2):1479-86 [17110380.001]
  • [Cites] J Biol Chem. 2007 May 11;282(19):14328-36 [17363372.001]
  • [Cites] Nature. 2007 Oct 11;449(7163):682-8 [17898713.001]
  • [Cites] Nature. 2008 Jan 10;451(7175):147-52 [18185580.001]
  • [Cites] Int J Cancer. 2008 May 1;122(9):2050-6 [18172859.001]
  • [Cites] Clin Cancer Res. 2008 May 1;14(9):2535-42 [18451214.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1279-83 [19190326.001]
  • [Cites] Clin Chem. 2009 Apr;55(4):623-31 [19246618.001]
  • [Cites] Cell Res. 2009 Apr;19(4):439-48 [19238171.001]
  • [Cites] BMC Cancer. 2009;9:163 [19473551.001]
  • [Cites] Annu Rev Med. 2009;60:167-79 [19630570.001]
  • [Cites] Pathobiology. 2009;76(5):235-42 [19816083.001]
  • [Cites] BMC Cancer. 2009;9:353 [19807914.001]
  • [Cites] J Clin Oncol. 2009 Dec 1;27(34):5848-56 [19884536.001]
  • [Cites] PLoS Genet. 2010 Mar;6(3):e1000879 [20300657.001]
  • [Cites] Oncogene. 2003 Aug 28;22(36):5572-8 [12944904.001]
  • (PMID = 20932331.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R03 CA123568
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / MIRN339 microRNA, human; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2958952
  •  go-up   go-down


9. Zhou S, Xu Z, Ling XF, Li QB, Xu YZ, Zhang L, Zhao HM, Wang LX, Hou KY, Zhou XS, Wu JG: [FTIR spectroscopic characterization of freshly removed breast cancer tissues]. Zhonghua Zhong Liu Za Zhi; 2006 Jul;28(7):512-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FTIR spectroscopic characterization of freshly removed breast cancer tissues].
  • OBJECTIVE: To identify the FTIR spectroscopic characterization of breast cancer and explore the possibility of application of FTIR in differentiation of malignant and benign breast lesions.
  • METHODS: FTIR spectra of surgically removed fresh breast tissues were measured by spectrometer equipped with mid-infrared fiber optics and an ATR probe.
  • Peaks in the spectra were measured and relative intensity ratios were calculated and analyzed if there are significant differences between the spectra of malignant and benign breast lesions.
  • RESULTS: There were significant differences (P < 0.05) between the spectra of malignant breast cancers and benign breast tissues in the relative intensity ratios of different peaks (I1640/ I1550 and I1160/I1120 for protein structures; I1640/I1460 and I1550/I1460 for relative content of protein and lipid; I1460/I1400 for lipid structures; I1310/I1240 for nucleic acid).
  • CONCLUSION: FTIR spectroscopy could be a useful tool in clinical diagnosis of breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Fibroadenoma / diagnosis. Spectroscopy, Fourier Transform Infrared / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast / chemistry. Breast / pathology. Female. Humans. Lipids / analysis. Middle Aged. Neoplasm Proteins / analysis. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147115.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Lipids; 0 / Neoplasm Proteins
  •  go-up   go-down


10. Harmer V: Breast cancer. Part 1: Awareness and common benign diseases. Br J Nurs; 2008 Aug 14-Sep 10;17(15):950-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer. Part 1: Awareness and common benign diseases.
  • Breast cancer is the most common cancer for women in the United Kingdom and topic on which there is much information.
  • This article discusses the principles behind breast awareness and breast health, detailing common benign breast diseases that cause disproportionate anxiety.
  • The NHS Breast Screening Programme is celebrating 20 years of screening this year, and in all randomized controlled trials of women aged 50 and over, mortality from breast cancer is reduced in those offered screening compared with unscreened controls (although the reduction is not statistically significant in all trials).
  • Once a breast cancer is diagnosed, the different characteristics and stage of the disease can be identified through histopathology and scans.
  • [MeSH-major] Breast Neoplasms / diagnosis
  • [MeSH-minor] Awareness. Diagnosis, Differential. England. Female. Humans. Mass Screening. Neoplasm Invasiveness. Referral and Consultation. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18983015.001).
  • [ISSN] 0966-0461
  • [Journal-full-title] British journal of nursing (Mark Allen Publishing)
  • [ISO-abbreviation] Br J Nurs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 33
  •  go-up   go-down


11. Petterino C, Ratto A, Arcicasa E, Podestà G, Drigo M, Pellegrino C: Expression of Stat3 in feline mammary gland tumours and its relation to histological grade. Vet Res Commun; 2006 Aug;30(6):599-611
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The samples included 3 normal nonlactating mammary tissues, 17 hyperplastic lesions (11 lobular and 6 fibroepithelial) and 52 neoplasms (5 benign and 47 malignant).
  • [MeSH-minor] Animals. Antibodies, Monoclonal. Biomarkers, Tumor / metabolism. Case-Control Studies. Cats. Female. Immunohistochemistry / veterinary. Linear Models. Mitotic Index. Neoplasm Staging / veterinary. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] Breast Cancer Res. 2000;2(2):86-90 [11250696.001]
  • [Cites] J Cell Physiol. 1998 May;175(2):220-8 [9525481.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] Vet J. 2004 Sep;168(2):180-5 [15301767.001]
  • [Cites] Int J Cancer. 1998 Oct 29;78(3):326-30 [9766567.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4A):2381-7 [9703883.001]
  • [Cites] J Clin Invest. 1998 Oct 1;102(7):1385-92 [9769331.001]
  • [Cites] Cell Growth Differ. 1997 Dec;8(12):1267-76 [9419415.001]
  • [Cites] J Virol. 1999 Feb;73(2):1689-94 [9882381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17 ):9148-53 [8799169.001]
  • [Cites] J Virol. 1997 Sep;71(9):6677-82 [9261390.001]
  • [Cites] Br J Cancer. 1995 Apr;71(4):840-4 [7710952.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6764-9 [9192639.001]
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5059-63 [10537273.001]
  • [Cites] Mol Cell Biol. 1998 May;18(5):2553-8 [9566875.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2645-56 [10851064.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2001 Jan;6(1):115-27 [11467447.001]
  • [Cites] Int J Oncol. 2001 Dec;19(6):1155-60 [11713584.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):978-87 [9041204.001]
  • [Cites] J Biol Chem. 1998 Oct 23;273(43):28065-72 [9774423.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Int J Oncol. 2000 Jul;17(1):23-8 [10853013.001]
  • [Cites] Blood. 1998 Jan 15;91(2):570-6 [9427711.001]
  • (PMID = 16838202.001).
  • [ISSN] 0165-7380
  • [Journal-full-title] Veterinary research communications
  • [ISO-abbreviation] Vet. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / STAT3 Transcription Factor
  •  go-up   go-down


12. Ma C, Quesnelle KM, Sparano A, Rao S, Park MS, Cohen MA, Wang Y, Samanta M, Kumar MS, Aziz MU, Naylor TL, Weber BL, Fakharzadeh SS, Weinstein GS, Vachani A, Feldman MD, Brose MS: Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues. Cancer Biol Ther; 2009 May;8(10):907-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization CSMD1 in a large set of primary lung, head and neck, breast and skin cancer tissues.
  • The Cub and Sushi Multiple Domains-1 (CSMD1) is a tumor suppressor gene on 8p23.2, where allelic loss is both frequent and associated with poor prognosis in head and neck squamous cell carcinoma (HNSCC).
  • To understand the extent of CSMD1 aberrations in vivo, we characterized 184 primary tumors from the head and neck, lung, breast and skin for gene copy number and analyzed expression in our HNSCCs and lung squamous cell carcinomas (SCCs).
  • We detected loss of CSMD1 in a large proportion of HNSCCs (50%), lung (46%) and breast cancers (55%), and to a lesser extent in cutaneous SCCs (29%) and basal cell carcinomas (BCCs, 17%) using array-based comparative genomic hybridization (aCGH).
  • CSMD1 expression was decreased in tumors compared to adjacent benign tissue (65%, 13/20) and was likely due to gene loss in 45% of cases (9/20).
  • We show loss of CSMD1 in primary HNSCC tissues, and document for the first time that CSMD1 is lost in breast, lung and cutaneous SCCs.
  • [MeSH-major] Breast Neoplasms / genetics. Head and Neck Neoplasms / genetics. Lung Neoplasms / genetics. Membrane Proteins / genetics. Skin Neoplasms / genetics
  • [MeSH-minor] Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Chromosome Deletion. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Female. Gene Dosage. Gene Expression. Humans. Loss of Heterozygosity. Mouth Neoplasms / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism


13. Belkacémi Y, Bousquet G, Marsiglia H, Ray-Coquard I, Magné N, Malard Y, Lacroix M, Gutierrez C, Senkus E, Christie D, Drumea K, Lagneau E, Kadish SP, Scandolaro L, Azria D, Ozsahin M: Phyllodes tumor of the breast. Int J Radiat Oncol Biol Phys; 2008 Feb 1;70(2):492-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor of the breast.
  • PURPOSE: To better identify prognostic factors for local control and survival, as well as the role of different therapeutic options, for phyllodes tumors, a rare fibroepithelial neoplasm of the breast.
  • Tumors were benign in 284 cases (64%), borderline in 80 cases (18%), and malignant in 79 cases (18%).
  • Surgery consisted of breast-conserving surgery (BCS) in 377 cases (85%) and total mastectomy (TM) in 66 cases (15%).
  • Multivariate analysis revealed benign histology, negative margins, and no residual disease (no RD) after initial treatment and RT delivery as independent favorable prognostic factors for local control; benign histology and low number of mitosis for disease-free survival; and pathologic tumor size < or = 3 cm and no tumor necrosis for overall survival.
  • CONCLUSIONS: This study showed that phyllodes tumor patients with no RD after treatment have better local control.
  • Benign tumors have a good prognosis after surgery alone.
  • [MeSH-major] Breast Neoplasms / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Child. Female. Follow-Up Studies. Humans. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Radiotherapy, Adjuvant. Survival Rate


14. Goyal S, Puri T, Gupta R, Julka PK, Rath GK: Accessory breast tissue in axilla masquerading as breast cancer recurrence. J Cancer Res Ther; 2008 Apr-Jun;4(2):95-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Accessory breast tissue in axilla masquerading as breast cancer recurrence.
  • Ectopic or accessory breast tissue is most commonly located in the axilla, though it may be present anywhere along the milk line.
  • Development is hormone dependent, similar to normal breast tissue.
  • These lesions do not warrant any intervention unless they produce discomfort, thus their identification and distinction from other breast pathologies, both benign and malignant, is essential.
  • We report a case with locally advanced breast cancer who presented with an ipsilateral axillary mass following surgery, radiotherapy, and chemotherapy.
  • Subsequent evaluation with excision biopsy showed duct ectasia in axillary breast tissue and the patient was continued on hormone therapy with tamoxifen.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Axilla. Biopsy. Chemotherapy, Adjuvant. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Mastectomy, Modified Radical. Neoplasm Staging. Parity. Pregnancy. Premenopause. Radiotherapy, Adjuvant. Recurrence. Tamoxifen / therapeutic use. Taxoids / therapeutic use. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688128.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Hormonal; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 15H5577CQD / docetaxel; 3Z8479ZZ5X / Epirubicin
  •  go-up   go-down


15. Jaremko M, Justenhoven C, Abraham BK, Schroth W, Fritz P, Brod S, Vollmert C, Illig T, Brauch H: MALDI-TOF MS and TaqMan assisted SNP genotyping of DNA isolated from formalin-fixed and paraffin-embedded tissues (FFPET). Hum Mutat; 2005 Mar;25(3):232-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We isolated constitutional DNA from 274 FFPET samples (229 patients with breast cancer and 45 patients with benign breast diseases) and genotyped 15 polymorphic loci in 10 genes.
  • Furthermore, genotype frequencies matched those observed in a German breast cancer population and other Caucasian populations.
  • [MeSH-minor] Alleles. Breast Diseases / genetics. Breast Diseases / pathology. Breast Neoplasms / genetics. Breast Neoplasms / pathology. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Formaldehyde. Genotype. Humans. Neoplasm Proteins / genetics. Paraffin Embedding. Taq Polymerase

  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15706592.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 1HG84L3525 / Formaldehyde; 9007-49-2 / DNA; EC 2.7.7.- / Taq Polymerase
  •  go-up   go-down


16. Königsberg R, Rögelsperger O, Jäger W, Thalhammer T, Klimpfinger M, De Santis M, Hudec M, Dittrich C: Cell cycle dysregulation influences survival in high risk breast cancer patients. Cancer Invest; 2008 Aug;26(7):734-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cell cycle dysregulation influences survival in high risk breast cancer patients.
  • Recent immunohistological studies suggested that dysregulation of cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), and p27(kip1) are of prognostic value in patients with breast cancer.
  • Our study represents the first comprehensive immunohistochemical cell cycle marker analysis for cdc25A, cyclin A, cyclin D, cyclin E, p16(ink4), p21(waf1/cip1), p27(kip1), and pRb in tumor tissue and adjacent benign breast tissue from 69 primarily untreated breast cancer patients.
  • RESULTS: Sixty-nine patients with untreated, invasive breast cancer (n = 69) were divided into a low/ intermediate and a high risk group according to the St. Gallen 2005 consensus conference.
  • A subgroup of high risk breast cancer patients characterized in addition by overexpression of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) experienced a shortened mean survival of 222.03, 235.71, 257.25, 239.18, and 261.94 weeks, respectively.
  • Regarding benign breast tissue adjacent to breast cancer tissue, 59.4% of the patients investigated overexpressed cdc25A, 23.2% overexpressed pRb, and 63.2% exerted dysregulation of p27(kip1) while they proved to be negative for immunohistochemical staining regarding all other markers tested.
  • CONCLUSION: The immunohistological analyses of cdc25A, cyclin A, cyclin E, p16(ink4a), and p27(kip1) have the potential for further refining the risk assessment in patients with untreated breast cancer who belong to the high risk category defined according to the St. Gallen 2005 consensus conference.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / chemistry. Breast Neoplasms / mortality. Cell Cycle. Cell Cycle Proteins / analysis. Cell Proliferation
  • [MeSH-minor] Adult. Cyclin A / analysis. Cyclin D. Cyclin E / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Cyclin-Dependent Kinase Inhibitor p21 / analysis. Cyclin-Dependent Kinase Inhibitor p27. Cyclins / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Intracellular Signaling Peptides and Proteins / analysis. Kaplan-Meier Estimate. Neoplasm Invasiveness. Proportional Hazards Models. Retinoblastoma Protein / analysis. Retrospective Studies. Risk Assessment. Treatment Outcome. cdc25 Phosphatases / analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665474.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / CDKN1B protein, human; 0 / Cell Cycle Proteins; 0 / Cyclin A; 0 / Cyclin D; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Cyclins; 0 / Intracellular Signaling Peptides and Proteins; 0 / Retinoblastoma Protein; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / CDC25A protein, human; EC 3.1.3.48 / cdc25 Phosphatases
  •  go-up   go-down


17. Flegg KM, Flaherty JJ, Bicknell AM, Jain S: Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program. World J Surg Oncol; 2010;8:78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcomes of borderline breast lesions detected by needle biopsy in a breast screening program.
  • This study describes the outcome of surgical biopsies of the breast performed as a result of a borderline lesion being identified after screening mammography and subsequent workup.A secondary aim was to identify any parameters, such as a family history of breast cancer, or radiological findings that may indicate which borderline lesions are likely to be upgraded to malignancy after surgery.
  • METHODS: From a period of just over eight years, all patients of BreastScreen ACT&SENSW who were diagnosed with a borderline breast lesion were identified.
  • RESULTS: Of the 94 surgical biopsies performed due to the presence of a borderline breast lesion, 20% showed benign pathology, 55% remained as borderline lesions, 17% showed non-invasive malignancy and 7% showed invasive malignancy.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / surgery. Mass Screening / methods. Mastectomy / methods. Neoplasm Staging / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. New South Wales. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 2000 Jun;135(6):700-3 [10843367.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1253-7 [17438578.001]
  • [Cites] Pathology. 2002 Oct;34(5):410-6 [12408338.001]
  • [Cites] Cancer. 2003 Jan 15;97(2):345-51 [12518358.001]
  • [Cites] Hum Pathol. 2003 Mar;34(3):234-9 [12673557.001]
  • [Cites] Adv Anat Pathol. 2003 May;10(3):113-24 [12717115.001]
  • [Cites] Radiology. 2004 Jun;231(3):813-9 [15105449.001]
  • [Cites] Histopathology. 2004 Aug;45(2):148-54 [15279633.001]
  • [Cites] N Engl J Med. 1999 Feb 11;340(6):430-6 [9971867.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Am J Surg Pathol. 2005 Apr;29(4):534-43 [15767810.001]
  • [Cites] Eur J Radiol. 2005 Apr;54(1):62-71 [15797294.001]
  • [Cites] Am J Surg. 2006 Oct;192(4):534-7 [16978969.001]
  • [Cites] AJR Am J Roentgenol. 2006 Oct;187(4):949-54 [16985141.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):35-41 [17095049.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):180-7 [17154175.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):704-11 [17151788.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):417-26 [17325484.001]
  • [Cites] Histopathology. 2007 Apr;50(5):607-14 [17394497.001]
  • [Cites] Am J Surg Pathol. 2002 Sep;26(9):1095-110 [12218567.001]
  • (PMID = 20822548.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2945347
  •  go-up   go-down


18. Oo KZ, Xiao PQ: Infiltrating syringomatous adenoma of the nipple: clinical presentation and literature review. Arch Pathol Lab Med; 2009 Sep;133(9):1487-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infiltrating syringomatous adenoma of the nipple is a rare neoplasm of the breast.
  • Despite its benign behavior, syringomatous adenoma of the nipple usually shows infiltrative expansile proliferation into adjacent tissue and underlying breast tissue.
  • Histologically and clinically, syringomatous adenoma of the nipple is often confused with tubular carcinoma as well as low-grade adenosquamous carcinoma of the breast.
  • Special attention given to this tumor by pathologists and clinicians can avoid misdiagnosis and unnecessary treatment.
  • [MeSH-major] Breast Neoplasms / pathology. Nipples / pathology. Sweat Gland Neoplasms / pathology. Syringoma / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adolescent. Adult. Aged. Child. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19722761.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


19. Kohler C, Radpour R, Barekati Z, Asadollahi R, Bitzer J, Wight E, Bürki N, Diesch C, Holzgreve W, Zhong XY: Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer; 2009;8:105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors.
  • METHODS: Using multiplex real-time PCR we investigated the levels of ccf nDNA and mtDNA in plasma samples from patients with malignant and benign breast tumors, and from healthy controls.
  • RESULTS: While the levels of ccf nDNA in the cancer group were significantly higher in comparison with the benign tumor group (P < 0.001) and the healthy control group (P < 0.001), the level of ccf mtDNA was found to be significantly lower in the two tumor-groups (benign: P < 0.001; malignant: P = 0.022).
  • The level of ccf nDNA was also associated with tumor-size (<2 cm vs. >2 cm<5 cm; 2250 vs. 6658; Mann-Whitney-U-Test: P = 0.034).
  • Using ROC curve analysis, we were able to distinguish between the breast cancer cases and the healthy controls using ccf nDNA as marker (cut-off: 1866 GE/ml; sensitivity: 81%; specificity: 69%; P < 0.001) and between the tumor group and the healthy controls using ccf mtDNA as marker (cut-off: 463282 GE/ml; sensitivity: 53%; specificity: 87%; P < 0.001).
  • CONCLUSION: Our data suggests that nuclear and mitochondrial ccf DNA have potential as biomarkers in breast tumor management.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Cell Nucleus / genetics. DNA, Mitochondrial / blood
  • [MeSH-minor] Case-Control Studies. Cell-Free System. Cohort Studies. Diagnosis, Differential. Female. Health. Humans. Lymph Nodes / pathology. Neoplasm Metastasis. ROC Curve. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Biotechnol. 2006 Aug;24(8):905-8 [16900126.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):629-38 [16568452.001]
  • [Cites] BMC Cancer. 2006;6:269 [17116247.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):157-63 [17280876.001]
  • [Cites] Mitochondrion. 2007 Feb-Apr;7(1-2):53-7 [17320491.001]
  • [Cites] Acta Paediatr. 2007 May;96(5):644-7 [17376185.001]
  • [Cites] Int J Biol Markers. 2007 Apr-Jun;22(2):95-9 [17549664.001]
  • [Cites] Arch Gynecol Obstet. 2007 Oct;276(4):327-31 [17431649.001]
  • [Cites] Prostate. 2008 Mar 1;68(4):408-17 [18196528.001]
  • [Cites] Clin Chem Lab Med. 2008;46(3):311-7 [18254709.001]
  • [Cites] JAMA. 2008 May 14;299(18):2151-63 [18477782.001]
  • [Cites] Anticancer Res. 2008 Mar-Apr;28(2A):921-5 [18507037.001]
  • [Cites] Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Jun;16(3):699-703 [18549658.001]
  • [Cites] Int J Biol Markers. 2008 Apr-Jun;23(2):69-73 [18629778.001]
  • [Cites] DNA Cell Biol. 2008 Aug;27(8):415-21 [18694299.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Obstet Gynecol. 2008 Oct;112(4):843-50 [18827127.001]
  • [Cites] Ann N Y Acad Sci. 2008 Aug;1137:175-9 [18837944.001]
  • [Cites] Cytokine. 2008 Oct;44(1):65-9 [18691902.001]
  • [Cites] Expert Rev Neurother. 2008 Dec;8(12):1841-52 [19086880.001]
  • [Cites] Neuroimage. 2009 Jun;46(2):394-410 [19236926.001]
  • [Cites] Clin Chem. 2000 Dec;46(12):1903-6 [11106320.001]
  • [Cites] Lancet. 2001 Jan 27;357(9252):310-1 [11214156.001]
  • [Cites] Swiss Med Wkly. 2001 Feb 10;131(5-6):70-4 [11383228.001]
  • [Cites] Ann N Y Acad Sci. 2001 Sep;945:138-40 [11708467.001]
  • [Cites] Clin Chim Acta. 2002 Jul;321(1-2):77-87 [12031596.001]
  • [Cites] Int J Gynaecol Obstet. 1995 Feb;48(2):187-92 [7540567.001]
  • [Cites] Lab Invest. 1996 Mar;74(3):592-9 [8600309.001]
  • [Cites] Brain Res Mol Brain Res. 1997 Dec 15;52(2):284-9 [9495550.001]
  • [Cites] Int J Cancer. 2005 Oct 10;116(6):920-4 [15856456.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1564-9 [16533782.001]
  • [Cites] Prenat Diagn. 2006 Apr;26(4):362-8 [16566058.001]
  • [Cites] Br J Cancer. 2006 Oct 23;95(8):1087-91 [17047655.001]
  • (PMID = 19922604.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Mitochondrial; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2780981
  •  go-up   go-down


20. Dillon MF, Hill AD, Quinn CM, O'Doherty A, McDermott EW, O'Higgins N: The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases. Ann Surg; 2005 Nov;242(5):701-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The accuracy of ultrasound, stereotactic, and clinical core biopsies in the diagnosis of breast cancer, with an analysis of false-negative cases.
  • OBJECTIVE: Preoperative core biopsy in breast cancer is becoming the standard of care.
  • METHODS: All patients undergoing core biopsy for breast abnormalities over a 5-year period (1999-2003) were reviewed.
  • The accuracy rates for each method of core biopsy, the histologic agreement between the core pathology and subsequent excision pathology, and the length of follow-up for cases of benign disease were studied.
  • Patients whose biopsies were benign but who were subsequently diagnosed with cancer underwent detailed review.
  • RESULTS: There were 2427 core biopsies performed over the 5-year period, resulting in a final diagnosis of cancer in 1384 patients, benign disease in 954 patients, and atypical disease in 89 patients.
  • False-negative biopsies occurred in 85 patients, and in 8 of these patients the diagnosis was delayed by greater than 2 months.
  • CONCLUSION: Ultrasound guidance should be used to perform core biopsies in evaluating all breast abnormalities visible on ultrasound.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Adult. Age Distribution. Aged. Breast Diseases / pathology. Breast Diseases / ultrasonography. Cohort Studies. Diagnosis, Differential. False Negative Reactions. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Dec 15;89(12):2538-46 [11135213.001]
  • [Cites] Radiology. 1999 Mar;210(3):799-805 [10207484.001]
  • [Cites] Cancer. 2001 Apr 25;93(2):146-50 [11309781.001]
  • [Cites] Ann Surg. 2001 Jun;233(6):769-77 [11371735.001]
  • [Cites] Eur J Surg Oncol. 2001 Apr;27(3):244-9 [11393185.001]
  • [Cites] J Vasc Interv Radiol. 2001 Nov;12(11):1313-7 [11698631.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):853-9 [12115488.001]
  • [Cites] Am J Surg. 2002 Oct;184(4):353-5 [12383901.001]
  • [Cites] J Ultrasound Med. 2002 Nov;21(11):1221-6 [12418763.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(1):52-6 [12504658.001]
  • [Cites] Radiology. 2003 Mar;226(3):779-82 [12601206.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1824-31 [12673707.001]
  • [Cites] Acta Radiol. 2003 Jul;44(4):387-91 [12846688.001]
  • [Cites] Surgery. 2003 Oct;134(4):523-6; discussion 526-8 [14605609.001]
  • [Cites] Breast J. 2003 Nov-Dec;9(6):491-3 [14616944.001]
  • [Cites] Cancer. 2003 Dec 25;99(6):357-64 [14681944.001]
  • [Cites] Cancer. 2004 Jan 15;100(2):245-51 [14716757.001]
  • [Cites] Acad Radiol. 2004 Mar;11(3):293-308 [15035520.001]
  • [Cites] Cancer. 1986 Jan 15;57(2):320-3 [3942963.001]
  • [Cites] Surg Gynecol Obstet. 1990 May;170(5):407-10 [2183373.001]
  • [Cites] Eur J Surg Oncol. 1991 Jun;17(3):237-9 [2044776.001]
  • [Cites] Br J Surg. 1992 Oct;79(10):1042-5 [1422715.001]
  • [Cites] Radiology. 1993 May;187(2):507-11 [8475299.001]
  • [Cites] Radiology. 1994 Sep;192(3):793-5 [8058949.001]
  • [Cites] Radiology. 1994 Nov;193(2):325-6; discussion 326-8 [7972737.001]
  • [Cites] Radiology. 1994 Nov;193(2):359-64 [7972743.001]
  • [Cites] AJR Am J Roentgenol. 1996 Feb;166(2):341-6 [8553943.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):773-7 [8756371.001]
  • [Cites] Clin Radiol. 1996 Aug;51(8):562-5 [8761393.001]
  • [Cites] Cancer Detect Prev. 1996;20(6):620-4 [8939348.001]
  • [Cites] Cancer. 1996 Dec 1;78(11):2340-5 [8941004.001]
  • [Cites] Radiology. 1997 Apr;203(1):151-7 [9122384.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):697-701 [9275881.001]
  • [Cites] J Am Coll Surg. 2000 Mar;190(3):299-303 [10703854.001]
  • [Cites] Br J Cancer. 2000 Mar;82(5):1017-21 [10737383.001]
  • [Cites] Radiology. 2000 Jul;216(1):255-9 [10887257.001]
  • [Cites] Ann Surg. 2000 Oct;232(4):542-8 [10998652.001]
  • [Cites] Clin Radiol. 1997 Oct;52(10):764-7 [9366536.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):932-9 [9637557.001]
  • [Cites] Radiology. 1998 Sep;208(3):717-23 [9722851.001]
  • [Cites] J Ultrasound Med. 2001 Jan;20(1):43-9 [11149527.001]
  • (PMID = 16244544.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1409862
  •  go-up   go-down


21. Gashi-Luci LH, Limani RA, Kurshumliu FI: Invasive ductal carcinoma within fibroadenoma: a case report. Cases J; 2009;2:174
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Fibroadenoma is the most common benign tumor of the female breast with the highest incidence before age 30.
  • CASE PRESENTATION: We present a rare case of a 39 years old female with invasive ductal carcinoma arising within fibroadenoma.
  • CONCLUSION: There is a low percentage of fibroadenomas harboring carcinoma; however, all breast lumps should be seriously managed; extirpation and histological examination is recommended.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Cancer. 2009 Jul-Sep;46(3):244-6 [19574682.001]
  • [Cites] Pathol Int. 1994 Dec;44(12):874-7 [7866572.001]
  • [Cites] N Engl J Med. 1994 Jul 7;331(1):10-5 [8202095.001]
  • [Cites] Am J Clin Pathol. 1991 May;95(5):614-22 [1850948.001]
  • [Cites] Surg Gynecol Obstet. 1985 Feb;160(2):99-104 [2982218.001]
  • [Cites] Can J Surg. 1985 Jul;28(4):372-4 [2990650.001]
  • [Cites] Am J Clin Pathol. 2001 May;115(5):736-42 [11345838.001]
  • [Cites] Major Probl Pathol. 1979;11:i-xvi, 1-466 [547120.001]
  • [Cites] Cancer. 1975 Feb;35(2):450-6 [1111920.001]
  • [Cites] Int J Clin Oncol. 2004 Aug;9(4):334-8 [15375712.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):572-4 [15297206.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):795-7 [12354814.001]
  • [Cites] Arch Pathol Lab Med. 1984 Jul;108(7):590-4 [6329129.001]
  • (PMID = 19946485.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2783130
  •  go-up   go-down


22. Strobel K, Haerle SK, Stoeckli SJ, Schrank M, Soyka JD, Veit-Haibach P, Hany TF: Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging; 2009 Jun;36(6):919-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten second cancers (18%) were located outside the aerodigestive tract (colon, five; stomach, lymphoma, breast, thymus and kidney, one each).
  • False-positive PET/CT findings were mainly related to benign FDG uptake in the intestine due to benign or precancerous polyps or physiological FDG uptake in other head and neck regions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neoplasms, Second Primary / diagnostic imaging. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / therapy. Positron-Emission Tomography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1173-8 [14623746.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2002 Jun;128(6):703-7 [12049568.001]
  • [Cites] Head Neck. 2002 Apr;24(4):345-9 [11933176.001]
  • [Cites] Neuroradiology. 2008 Nov;50(11):969-79 [18600319.001]
  • [Cites] Radiother Oncol. 2008 May;87(2):221-9 [18410977.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Feb;124(2):208-12 [11226943.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jul;137(1):130-7 [17599580.001]
  • [Cites] Head Neck. 2007 Nov;29(11):986-95 [17563906.001]
  • [Cites] Head Neck. 1989 Sep-Oct;11(5):426-30 [2807882.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1804-10 [15534047.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jul-Aug;23 (4):603-8 [10433294.001]
  • [Cites] Cancer. 1995 Mar 15;75(6):1343-53 [7882285.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):434-8 [3661848.001]
  • [Cites] Nucl Med Commun. 2005 Aug;26(8):671-87 [16000985.001]
  • [Cites] Oral Oncol. 2006 Mar;42(3):275-80 [16266820.001]
  • [Cites] Laryngoscope. 2007 Jul;117(7):1173-9 [17603315.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Sep;17(3):467-76 [2674075.001]
  • [Cites] Laryngoscope. 2003 May;113(5):888-91 [12792328.001]
  • [Cites] Ann Nucl Med. 2006 Nov;20(9):597-604 [17294670.001]
  • [Cites] Oral Oncol. 2003 Sep;39(6):547-51 [12798396.001]
  • [Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]
  • [Cites] Am J Surg. 1964 Oct;108:552-7 [14211447.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1129-32 [15100107.001]
  • (PMID = 19205699.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


23. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, Welch DR, Lobo-Ruppert SM, Ruppert JM, Johnson MR, Frost AR: Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther; 2006 Jun;5(6):674-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer.
  • Using real-time, quantitative PCR, laser capture microdissection, and immunohistochemistry, distinctive patterns of expression of the hedgehog pathway members patched 1 (PTCH1), smoothened, GLI1, GLI2 and the 3 hedgehog ligands were identified for epithelial cells and stromal fibroblasts in benign breast and breast cancer.
  • GLI1 protein and mRNA, and PTCH1 and sonic hedgehog (SHH) proteins were elevated in 3 of 10 breast cancers; however, PTCH1 transcripts were not consistently increased.
  • Hedgehog-mediated transcription, as indicated by a reporter of GLI-dependent promoter activity and by expression of GLI1 transcripts, was reduced by the hedgehog pathway inhibitor cyclopamine in both MDA-MB-435 cancer epithelial cells and MCF10AT epithelial cells, a cell line derived from benign breast.
  • However, cyclopamine reduced viability of cancer epithelial cell lines, including MDA-MB-435, but did not specifically affect fibroblasts or epithelial cells from benign breast, including MCF10AT.
  • These results demonstrate modulation of GLI-mediated transcription in both cancer and benign-derived epithelial cells by cyclopamine and sonic hedgehog, and further suggest that hedgehog signaling contributes to the survival of only the cancer epithelial cells.
  • Determination as to whether the increase in GLI1 and SHH expression in breast cancer indicates a significant increase in hedgehog signaling will require further evaluation.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYCLOPAMINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histol Histopathol. 2002 Apr;17(2):623-37 [11962762.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):1883-90; discussion 1895-6 [16488983.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):923-8 [12615704.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):313-7 [12629553.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):508-13 [12652302.001]
  • [Cites] J Endocrinol. 2003 Sep;178(3):467-78 [12967338.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):851-6 [14520413.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 6;314(2):313-20 [14733907.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):903-11 [14737121.001]
  • [Cites] Biochem J. 2004 Mar 1;378(Pt 2):353-62 [14611647.001]
  • [Cites] J Agric Food Chem. 2004 May 19;52(10):2832-9 [15137822.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3479-85 [15150101.001]
  • [Cites] Int J Cancer. 2004 Jul 20;110(6):831-7 [15170664.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2577-85 [15277480.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2004 Apr;9(2):165-81 [15300011.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12561-6 [15314219.001]
  • [Cites] Cancer Res. 2004 Sep 1;64(17):6071-4 [15342389.001]
  • [Cites] Development. 2004 Oct;131(20):5009-19 [15371305.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] Int J Mol Med. 2004 Nov;14(5):793-9 [15492847.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):6075-86 [1975513.001]
  • [Cites] Science. 1997 May 2;276(5313):817-21 [9115210.001]
  • [Cites] Cancer Res. 1997 Jun 15;57(12):2369-72 [9192811.001]
  • [Cites] Science. 1998 Jun 5;280(5369):1603-7 [9616123.001]
  • [Cites] Eur J Cancer. 1999 May;35(5):711-3 [10505029.001]
  • [Cites] Mol Cancer. 2004 Oct 13;3:29 [15482598.001]
  • [Cites] Breast Cancer Res. 2005;7(1):R46-59 [15642169.001]
  • [Cites] Development. 1999 Nov;126(22):5181-93 [10529434.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Sep;8(3):236-43 [10981877.001]
  • [Cites] Nature. 2001 Feb 1;409(6820):633-7 [11214324.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1320-6 [11245428.001]
  • [Cites] J Invest Dermatol. 2001 Mar;116(3):472-4 [11231326.001]
  • [Cites] Semin Cancer Biol. 2001 Apr;11(2):97-104 [11322829.001]
  • [Cites] Dev Biol. 2001 Oct 1;238(1):133-44 [11783999.001]
  • [Cites] Int J Cancer. 2002 Mar 1;98(1):118-27 [11857395.001]
  • [Cites] Anal Biochem. 2002 Apr 15;303(2):209-14 [11950223.001]
  • [Cites] Histol Histopathol. 2002 Apr;17(2):599-621 [11962761.001]
  • [Cites] Dev Biol. 2005 Apr 1;280(1):111-21 [15766752.001]
  • [Cites] Genomics. 2005 Apr;85(4):462-71 [15780749.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):306-17 [15803137.001]
  • [Cites] Cell. 2005 May 6;121(3):335-48 [15882617.001]
  • [Cites] Development. 2005 Jul;132(14):3267-79 [15983404.001]
  • [Cites] J Neurosci. 2005 Sep 7;25(36):8338-46 [16148242.001]
  • [Cites] Carcinogenesis. 2005 Oct;26(10):1698-705 [15905200.001]
  • [Cites] Int J Cancer. 2006 Jan 1;118(1):139-48 [16003737.001]
  • [Cites] Hum Mol Genet. 2005 Nov 15;14(22):3379-88 [16203740.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • (PMID = 16855373.001).
  • [ISSN] 1538-4047
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA091421; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / R01 CA087728; United States / NCI NIH HHS / CA / R03 CA105950
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Hedgehog Proteins; 0 / RNA, Neoplasm; 0 / SHH protein, human; 0 / Veratrum Alkaloids; ZH658AJ192 / cyclopamine
  • [Other-IDs] NLM/ NIHMS11622; NLM/ PMC1557635
  •  go-up   go-down


24. Schulz-Wendtland R, Bock K, Aichinger U, de Waal J, Bader W, Albert US, Duda VF: [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?]. Ultraschall Med; 2005 Jun;26(3):209-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ultrasound examination of the breast with 7.5 MHz and 13 MHz-transducers: scope for improving diagnostic accuracy in complementary breast diagnostics?].
  • [Transliterated title] Mamma-Sonographie mit 7.5 MHz versus 13 MHz: Ist eine Verbesserung der diagnostischen Sicherheit im Rahmen der komplementären Mammadiagnostik möglich?
  • AIM: Complementary diagnostic methods in early diagnosis of breast cancer are used to increase diagnostic accuracy and minimize unnecessary invasive diagnostic procedures.
  • Aim of the following prospective, open multicenter clinical study was to define the value of high-frequency breast ultrasound with 13 MHZ transducers compared to standard breast ultrasound with 7.5 MHz.
  • METHOD: Data of 810 female patients, aged 45 to 60 years, with 819 suspicious breast lesions evaluated by four participating centres between October 1996 and December 1997.
  • Standardised breast ultrasound was performed uniformly using a AU4 IDEA diagnostic ultrasound system by Esaote-Biomedica in addition to a standardised procedure of clinical examination and standard-2view-mammography.
  • RESULTS: The histopathological evaluation showed 435 benign and 384 malignant findings.
  • High-frequency breast ultrasound (13 MHz) proved to have a higher diagnostic accuracy compared to standard breast ultrasound (7,5 MHz) regardless of tumour size.
  • CONCLUSIONS: We conclude that high-frequency ultrasound is a valueable additive tool especially in the diagnosis of small tumours, improving diagnostic safety and reducing unnecessary invasive diagnostic procedures.
  • [MeSH-major] Breast Diseases / ultrasonography. Breast Neoplasms / ultrasonography. Ultrasonography, Mammary / methods
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15948057.001).
  • [ISSN] 0172-4614
  • [Journal-full-title] Ultraschall in der Medizin (Stuttgart, Germany : 1980)
  • [ISO-abbreviation] Ultraschall Med
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Tse GM, Tan PH, Moriya T: The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2009 May;62(5):407-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast.
  • Papillary lesions of the breast represent a heterogeneous group with differing biological behaviour.
  • Correct diagnosis is crucial but may be difficult, as many benign and malignant papillary lesions have similar appearances.
  • A panel of CK5/6, p63 and neuroendocrine markers can be useful in the diagnostic investigation of problematic papillary lesions of the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Papillary / diagnosis. Papilloma / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoma, Intraductal, Noninfiltrating / diagnosis. Diagnosis, Differential. Female. Humans. Keratins / analysis. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126567.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 33
  •  go-up   go-down


26. Hao RT, Zhang XH, Pan YF, Liu HG, Xiang YQ, Wan L, Wu XL: Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer. J Cancer Res Clin Oncol; 2010 Sep;136(9):1349-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and metastatic value of phosphatase of regenerating liver-3 in invasive breast cancer.
  • PURPOSE: The aim of this study was to investigate the expression of the PRL-3 in human invasive breast cancer and to evaluate its clinical and prognostic significance.
  • Its potential role in the invasive-metastatic properties of invasive breast cancer was also investigated.
  • METHODS: Protein expression of PRL-3 was evaluated by immunohistochemistry for a consecutive series of 82 invasive human breast cancer tissues and 63 matched lymph node metastases, including PRL-3 mRNA expression analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) in malignant, nonmalignant breast tissue samples and lymph node metastases.
  • Moreover, The PRL-3 mRNA expression was significantly higher in malignant compared to benign breast tissue, while increased expression of PRL-3 mRNA was significantly associated with LNM (P = 0.002).
  • Increasing the risk of tumor metastasis (OR = 3.889).
  • Our results also imply that PRL-3 might be a novel molecular marker for predicting relapse of invasive breast cancer.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / enzymology. Neoplasm Proteins / metabolism. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Invasiveness / diagnosis. Prognosis. RNA, Messenger / biosynthesis. Recurrence. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Mol Med. 2008 Aug;22(2):187-92 [18636172.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 25;283(5):1061-8 [11355880.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1517-22 [16873432.001]
  • [Cites] Pathobiology. 2004;71(4):176-84 [15263806.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):2922-6 [17409395.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Sep;130(9):521-6 [15133662.001]
  • [Cites] Mol Med. 2007 Mar-Apr;13(3-4):151-9 [17592549.001]
  • [Cites] Arch Pathol Lab Med. 2008 Aug;132(8):1307-12 [18684031.001]
  • [Cites] Am J Pathol. 2004 Jun;164(6):2039-54 [15161639.001]
  • [Cites] Virchows Arch. 2007 Mar;450(3):303-10 [17235563.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21444-52 [10747914.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 15;348(1):229-37 [16875667.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2195-204 [15788667.001]
  • [Cites] Int J Colorectal Dis. 2007 Oct;22(10):1179-84 [17440740.001]
  • [Cites] Clin Cancer Res. 2003 Nov 15;9(15):5607-15 [14654542.001]
  • [Cites] Surg Today. 2007;37(8):646-51 [17643206.001]
  • [Cites] Mol Cell Biol. 1994 Jun;14(6):3752-62 [8196618.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7857-66 [15520192.001]
  • [Cites] Int J Cancer. 2008 Sep 15;123(6):1439-47 [18561324.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Mar 31;342(1):179-83 [16472776.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3153-61 [16540666.001]
  • [Cites] Cancer Lett. 1996 Dec 20;110(1-2):49-55 [9018080.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7318-28 [15534108.001]
  • [Cites] Science. 2001 Nov 9;294(5545):1343-6 [11598267.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2716-22 [12782572.001]
  • [Cites] Science. 2001 Oct 12;294(5541):281-2 [11598274.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):219-29 [16505094.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6835-9 [16203771.001]
  • [Cites] J Biol Chem. 2004 Mar 19;279(12):11882-9 [14704153.001]
  • [Cites] Br J Cancer. 2006 Aug 7;95(3):347-54 [16832410.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9625-35 [17018620.001]
  • [Cites] Biochem Biophys Res Commun. 1998 Mar 17;244(2):421-7 [9514946.001]
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):945-51 [15326366.001]
  • [Cites] Mol Cell. 2008 May 9;30(3):303-14 [18471976.001]
  • (PMID = 20140626.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; EC 3.1.3.48 / PTP4A3 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatases
  •  go-up   go-down


27. Subramanian A, Sharma AK, Banerjee D, Jiang WG, Mokbel K: Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer. Anticancer Res; 2007 Sep-Oct;27(5B):3513-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence for a tumour suppressive function of IGF1-binding proteins in human breast cancer.
  • The aim of this study was to determine the levels of mRNA expression of insulin-like growth factor-binding protein (IGFBP)-1, -3 and -7 genes in benign and malignant breast tissue and explore their relationship with various prognostic parameters.
  • MATERIALS AND METHODS: Breast cancer tissue (n=127) and normal background tissue (n-33) were prospectively collected and analysed for levels of IGFBP-1, -3 and -7 mRNA using real-time Q-PCR. mRNA levels were then analysed against tumour grade, nodal status, Nottingham prognostic index (NPI)/TNM stage and tumour type.
  • CONCLUSION: This study supports the role of IGFBP-1, -3 and -7 as potential tumour suppressor genes in human breast cancer.
  • [MeSH-major] Breast Neoplasms / genetics. Gene Expression Regulation, Neoplastic. Insulin-Like Growth Factor Binding Proteins / genetics. Insulin-Like Growth Factor Binding Proteins / metabolism. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Female. Humans. Neoplasm Staging. RNA, Messenger / genetics. RNA, Messenger / metabolism. Receptors, Estrogen / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972510.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


28. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • L1 was absent in breast carcinoma, gastrointestinal tract carcinomas, gastrointestinal carcinoids, renal clear-cell carcinomas, prostate adenocarcinomas, and mesotheliomas.
  • Surprisingly, L1 expression in established breast and renal carcinoma cell lines was not a predictor for its presence in these human tumors in vivo.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


29. Kelly RJ, Barrett C, Swan N, McDermott R: Metastatic phyllodes tumor causing small-bowel obstruction. Clin Breast Cancer; 2009 Aug;9(3):193-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic phyllodes tumor causing small-bowel obstruction.
  • Cystosarcoma phyllodes is an important but relatively uncommon fibroepithelial breast neoplasm that accounts for 0.5%-1.0% of female breast carcinomas.
  • This report highlights a unique case of a metastatic phyllodes breast tumor leading to small bowel obstruction.
  • Phyllodes tumors are generally classified into histologic subtypes of benign, intermediate, and malignant, using agreed classification systems.
  • The tumor characteristics that can lead to the dedifferentiation of a relatively benign phenotype to an overt malignant process are discussed.
  • [MeSH-major] Breast Neoplasms / pathology. Ileal Neoplasms / secondary. Intestinal Obstruction / etiology. Phyllodes Tumor / pathology
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Combined Modality Therapy. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mastectomy. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661046.001).
  • [ISSN] 1938-0666
  • [Journal-full-title] Clinical breast cancer
  • [ISO-abbreviation] Clin. Breast Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


30. Grenier J, Delbaldo C, Zelek L, Piedbois P: [Phyllodes tumors and breast sarcomas: a review]. Bull Cancer; 2010 Oct;97(10):1197-207
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phyllodes tumors and breast sarcomas: a review].
  • [Transliterated title] Tumeurs phyllodes et sarcomes du sein: mise au point.
  • Phyllodes tumors and sarcomas of the breast are non-epithelial tumors of the breast.
  • Phyllodes tumors are benign tumors, tumors of intermediate malignancy or malignant tumors.
  • The differential diagnosis with a very proliferant fibroadenoma may be difficult.
  • Radiotherapy is recommended in case of high-grade tumor and after conservativetreatment.
  • Breast sarcomas are even rarer.
  • Grade, involved margins and sometimes tumor necrosis are major prognostics factors.
  • In some situations, a conservative treatment can be discussed, based on tumor size, grade and volume of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Phyllodes Tumor / pathology. Sarcoma / pathology
  • [MeSH-minor] Female. Hemangiosarcoma / pathology. Hemangiosarcoma / secondary. Hemangiosarcoma / therapy. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855241.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  •  go-up   go-down


36. Brennan ME, Houssami N, Lord S, Macaskill P, Irwig L, Dixon JM, Warren RM, Ciatto S: Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol; 2009 Nov 20;27(33):5640-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management.
  • PURPOSE: Preoperative magnetic resonance imaging (MRI) is increasingly used for staging women with breast cancer, including screening for occult contralateral cancer.
  • This article is a review and meta-analysis of studies reporting contralateral MRI in women with newly diagnosed invasive breast cancer.
  • CONCLUSION: MRI detects contralateral lesions in a substantial proportion of women, but does not reliably distinguish benign from malignant findings.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / surgery. Magnetic Resonance Imaging / methods. Mass Screening / methods. Neoplasms, Second Primary / diagnosis
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Cohort Studies. False Negative Reactions. False Positive Reactions. Female. Humans. Incidence. Logistic Models. Mastectomy / methods. Middle Aged. Neoplasm Staging / methods. Predictive Value of Tests. Preoperative Care / methods. Risk Assessment. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805685.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 47
  •  go-up   go-down


37. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


38. Martínez-Galán J, Torres B, Del Moral R, Muñoz-Gámez JA, Martín-Oliva D, Villalobos M, Núñez MI, Luna Jde D, Oliver FJ, Ruiz de Almodóvar JM: Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy. Cancer Biol Ther; 2008 Jun;7(6):958-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative detection of methylated ESR1 and 14-3-3-sigma gene promoters in serum as candidate biomarkers for diagnosis of breast cancer and evaluation of treatment efficacy.
  • The aim of the present study was to investigate the association between gene hypermethylation and main clinicopathological features of breast cancer, including diagnosis and treatment response.
  • A sensitive SYBR green methylation-specific PCR technique was used to analyze the utility of circulating DNA with CpG island hypermethylation of ESR1, APC, RARB, 14-3-3-sigma and E-cad gene promoter regions as breast cancer biomarkers.
  • Analyses were conducted of preoperative sera from 106 women with breast cancer, 34 with benign breast disease and 74 with no evidence of breast disease and of post-treatment sera from 60 of the breast cancer patients.
  • Mean serum values of methylated ESR1 and 14-3-3-sigma gene promoters significantly differed between breast cancer patients and healthy controls (p = 0.0112 for ESR1 and p = 0.0047 for 14-3-3-sigma).
  • When their results were combined, it was found that hypermethylation of these two genes differentiated between breast cancer patients and healthy controls (p < 0.0001) with a sensitivity of 81% (95% confidence interval: 72-88%) and specificity of 88% (95% CI: 78-94%).
  • Presence of methylated ESR1 in serum of breast cancer patients was associated with the ER negative phenotype (p = 0.0179).
  • Serum hypermethylation at ESR1 and 14-3-3-sigma loci was observed in cancer patients, in situ carcinoma and benign breast disease.
  • Preliminary clinical applications of this approach have revealed several shortcomings, including a frequent presence of methylated 14-3-3-sigma in sera from women with breast benign disease.
  • These findings cast some doubts on the utility for early cancer diagnosis of highly sensitive techniques to identify hypermethylation of specific gene promoters in DNA extracted from serum.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / blood. Breast Neoplasms / diagnosis. Estrogen Receptor alpha / metabolism. Exonucleases / metabolism. Neoplasm Proteins / metabolism
  • [MeSH-minor] 14-3-3 Proteins. Case-Control Studies. DNA Methylation. DNA, Neoplasm / metabolism. Disease Progression. Exoribonucleases. Female. Humans. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Sensitivity and Specificity. Treatment Outcome


39. Uematsu T, Kasami M: Risk of needle tract seeding of breast cancer: cytological results derived from core wash material. Breast Cancer Res Treat; 2008 Jul;110(1):51-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of needle tract seeding of breast cancer: cytological results derived from core wash material.
  • Needle track seeding has been recognized as a possible, albeit rare, complication of breast core needle biopsy.
  • The purpose of this study was to assess the risk of needle tract seeding of breast cancer from cytological results derived from core needle wash material.
  • The study included biopsies of 207 breast cancers performed using ultrasonographically guided 18-gauge core needles.
  • The cytological diagnoses were divided into five categories: benign, atypical/indeterminate, suspicious/probably malignant, malignant and unsatisfactory.
  • Atypical/indeterminate, suspicious/probably malignant and malignant categories were considered to represent positive cases of needle track seeding of breast cancer, whereas benign and unsatisfactory categories were counted as negative cases.
  • Cytological diagnoses of the 207 lesions were as follows: 26 lesions (12%) were benign, 18 lesions (9%) were atypical/indeterminate, 37 lesions (18%) were suspicious/probably malignant, 79 lesions (38%) were malignant, and 47 lesions (23%) were unsatisfactory.
  • In conclusion, the incidence of positive cases of cytology derived from ultrasonographically guided breast core needles' wash material was 65%.
  • [MeSH-major] Biopsy, Needle / adverse effects. Breast Neoplasms / pathology. Neoplasm Seeding
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Lobular / pathology. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674195.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Sanders ME, Page DL, Simpson JF, Schuyler PA, Dale Plummer W, Dupont WD: Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies. Cancer; 2006 Apr 1;106(7):1453-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interdependence of radial scar and proliferative disease with respect to invasive breast carcinoma risk in patients with benign breast biopsies.
  • BACKGROUND: Radial scars (RS) are benign breast lesions that have been implicated as independent risk factors for invasive breast carcinoma (IBC).
  • METHODS: A retrospective cohort study of 9556 women who underwent biopsy between 1950-1986 and enrolled in the Nashville Breast Cohort was performed to investigate the association between RS in a benign breast biopsy and the risk of IBC.
  • Although the presence of RS in a benign breast biopsy mildly elevates the risk of IBC risk, the current analysis indicated that this risk can be largely attributed to the category of coexistent PD.
  • [MeSH-major] Breast / pathology. Breast Diseases / complications. Breast Neoplasms / etiology. Carcinoma / etiology
  • [MeSH-minor] Adult. Aged. Biopsy. Case-Control Studies. Female. Humans. Hyperplasia / complications. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16502407.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA68485; United States / NCI NIH HHS / CA / P50-CA098131; United States / NCI NIH HHS / CA / R01-CA50468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


41. Britton PD, Goud A, Godward S, Barter S, Freeman A, Gaskarth M, Rajan P, Sinnatamby R, Slattery J, Provenzano E, O'Donovan M, Pinder S, Benson JR, Forouhi P, Wishart GC: Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. Eur Radiol; 2009 Mar;19(3):561-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer.
  • The aim of this study was to see how effective ultrasound-guided needle biopsy was at detecting lymph node involvement in patients with early breast cancer.
  • Patients with newly diagnosed invasive breast cancer underwent axillary ultrasound (US) where lymph node size and morphology were noted.
  • Patients with benign CBs proceeded to sentinel lymph node (SLN) biopsy, whereas those with malignancy underwent axillary lymph node dissection (ALND).
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / diagnostic imaging. Lymph Nodes / diagnostic imaging. Lymph Nodes / pathology. Neoplasm Staging / methods. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla / pathology. Early Detection of Cancer. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Sensitivity and Specificity. Ultrasonography

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2003 May;39(8):1068-73 [12736105.001]
  • [Cites] Radiology. 1992 Apr;183(1):215-20 [1549675.001]
  • [Cites] Eur J Cancer. 2003 Jan;39(2):170-4 [12509948.001]
  • [Cites] Radiology. 2002 Nov;225(2):527-36 [12409591.001]
  • [Cites] Eur Radiol. 2006 Oct;16(10 ):2153-60 [16670863.001]
  • [Cites] Br J Surg. 1999 Nov;86(11):1459-62 [10583296.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):203-8 [16541308.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):141-5 [11289748.001]
  • [Cites] Br J Cancer. 2003 Mar 10;88(5):702-6 [12618878.001]
  • [Cites] Cancer. 1983 Nov 1;52(9):1551-7 [6352003.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):982-8 [12209680.001]
  • [Cites] Radiology. 2004 Feb;230(2):543-52 [14699178.001]
  • [Cites] AJR Am J Roentgenol. 2001 Apr;176(4):1069-74 [11264113.001]
  • [Cites] Radiology. 2004 Mar;230(3):727-34 [14990839.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):31-5 [16372147.001]
  • [Cites] Br J Cancer. 2003 Oct 6;89(7):1310-3 [14520465.001]
  • [Cites] Eur J Radiol. 2005 Dec;56(3):382-5 [16024205.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):358-67 [15593354.001]
  • [Cites] Lancet Oncol. 2006 Dec;7(12):983-90 [17138219.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23 (30):7703-20 [16157938.001]
  • [Cites] World J Surg. 1997 Mar-Apr;21(3):270-4 [9015169.001]
  • [Cites] Eur J Cancer. 2003 May;39(8):1037-8 [12736100.001]
  • [Cites] Can Assoc Radiol J. 2005 Dec;56(5):289-96 [16579022.001]
  • [Cites] Lancet Oncol. 2007 Oct;8(10):881-8 [17851130.001]
  • [Cites] Radiology. 1997 Dec;205(3):831-5 [9393544.001]
  • (PMID = 18797874.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


42. Catalano F, Furci M, Fancello R, Costanzo M: Giant recurrent fibromatosis of the breast: a case report. Clinical features and implications for treatment. Chir Ital; 2006 Jul-Aug;58(4):538-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant recurrent fibromatosis of the breast: a case report. Clinical features and implications for treatment.
  • Fibromatosis of the breast is a benign but locally aggressive neoplasm, which has been described under various names including extra-abdominal desmoid tumour and aggressive fibromatosis.
  • It is a rare condition, accounting for approximately 0.2% of all solid tumours of the breast.
  • Clinically and radiologically the lesion mimics breast cancer and the definitive diagnosis is provided by histology.
  • The possible association between breast implants and mammary fibromatosis has been reported.
  • In this study we report a case of giant fibromatosis of the breast observed in a young patient and its extensive recurrence, involving all quadrants of the breast, the pectoralis major muscle, the rectus abdominis muscle sheath and the costal layer.
  • The main clinical and pathological characteristics of this rare disease are illustrated, emphasizing the difficulties encountered both in the diagnosis of the primary lesion and in the management of its giant recurrence, particularly as regards the possibility of obtaining a radical surgical excision and the option of performing breast reconstruction.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / surgery. Fibromatosis, Aggressive / diagnosis. Fibromatosis, Aggressive / surgery
  • [MeSH-minor] Adult. Female. Humans. Mastectomy. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / surgery. Pectoralis Muscles / pathology. Pectoralis Muscles / surgery. Rectus Abdominis / pathology. Rectus Abdominis / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999161.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


43. Karim RZ, Gerega SK, Yang YH, Spillane A, Carmalt H, Scolyer RA, Lee CS: p16 and pRb immunohistochemical expression increases with increasing tumour grade in mammary phyllodes tumours. Histopathology; 2010 Jun;56(7):868-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Control of cell cycling and proliferation is critical to the development of neoplasia and may play a role in the pathogenesis of phyllodes tumours (PTs).
  • METHODS AND RESULTS: Sixty-five PTs (34 benign, 23 borderline and eight malignant) diagnosed at a single institution between 1990 and 2006 were analysed.
  • [MeSH-major] Breast Neoplasms / metabolism. Neoplasm Proteins / metabolism. Phyllodes Tumor / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Blotting, Western. Cyclin D1 / metabolism. Disease-Free Survival. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Tissue Array Analysis


44. Xing Y, Zhao JH, Wang TS, Qiao WL, Che WJ: [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers]. Zhonghua Zhong Liu Za Zhi; 2009 Feb;31(2):129-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The role of 18F-FDG SPECT-CT in detecting recurrence and metastases in breast cancer patients with elevated tumor markers].
  • OBJECTIVE: To compare retrospectively the role of (18)F-FDG SPECT-CT and conventional imaging in the detection of recurrence and metastases in postoperative breast cancer patients with elevated level of tumor markers, and to evaluate the impact of (18)F-FDG SPECT-CT on the management of breast cancer patients.
  • METHODS: (18)F-FDG SPECT-CT was performed in 35 breast cancer patients with suspected recurrence based on elevated level of serum tumor markers.
  • The final diagnosis of recurrent breast cancer was confirmed by either pathology or observation by imaging during the follow-up for more than 1 year.
  • RESULTS: Among the 35 patients, the final diagnosis of recurrence or metastasis was established in 19 patients.
  • Of the 114 sites of increased FDG uptake, 93 were interpreted as malignant and 21 as benign.
  • CONCLUSION: In postoperative breast cancer patients with elevated level of tumor markers during the follow-up, (18)F-FDG SPECT-CT is more sensitive for detecting recurrence and metastases than conventional imaging.
  • [MeSH-major] Breast Neoplasms / pathology. Fluorodeoxyglucose F18. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Breast Neoplasms, Male / blood. Breast Neoplasms, Male / pathology. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Male. Middle Aged. Radiopharmaceuticals. Retrospective Studies. Whole Body Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538891.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


45. Huang ZH, Li LH, Hua D: Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett; 2006 Nov 8;243(1):64-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients.
  • The aim of the present project was to quantify the level of plasma DNA in patients with malignant or non-malignant breast diseases and in healthy controls, then investigate whether such measurements have diagnostic or prognostic value.
  • Plasma DNA from 121 women (61 patients with breast cancer, 33 control patients with benign breast diseases and 27 healthy control individuals) was quantified by a real-time quantitative polymerase chain reaction (PCR) method.
  • Plasma DNA concentration in the breast cancer patients (median 65 ng/ml) was significantly higher (P<0.05) than that in the control patients (median 22 ng/ml) or healthy control (median 13 ng/ml).
  • The data suggest that quantification of plasma circulating DNA may be a valuable complementary diagnostic tool in discriminate breast cancer from unaffected individuals and may be proposed as an early detection test as well as a new, noninvasive assay to follow-up patients.
  • [MeSH-major] Breast Neoplasms / diagnosis. DNA, Neoplasm / blood
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Middle Aged. Retrospective Studies. Sensitivity and Specificity. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16412565.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


46. Kothandaraman N, Bajic VB, Brendan PN, Huak CY, Keow PB, Razvi K, Salto-Tellez M, Choolani M: E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer. BMC Cancer; 2010;10:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] E2F5 status significantly improves malignancy diagnosis of epithelial ovarian cancer.
  • Our hypothesis was supported by our tissue array experiments that showed E2F5 expression only in OEC samples but not in normal and benign tissues, and by significantly positively biased expression in serum samples done using western blotting studies.
  • E2F5 used in different combinations with CA125 for distinguishing malignant cyst from benign cyst shows that the presence of CA125 or E2F5 increases sensitivity of OEC detection to 97.9% (an increase from 87.5% if only CA125 is used) and, more importantly, the presence of both CA125 and E2F5 increases specificity of OEC to 72.5% (an increase from 55% if only CA125 is used).
  • Furthermore, detection of malignancy status in 86 cases (38 benign, 48 early and late OEC) shows that the use of E2F5 status in combination with other clinical characteristics allows for an improved detection of malignant cases with sensitivity, specificity, F-measure and accuracy of 97.92%, 97.37%, 97.92% and 97.67%, respectively.
  • CONCLUSIONS: Overall, our findings, in addition to opening a realistic possibility for improved OEC diagnosis, provide an indirect evidence that a cell-cycle regulatory protein E2F5 might play a significant role in OEC pathogenesis.
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor / metabolism. CA-125 Antigen / biosynthesis. Disease Progression. Female. Humans. Middle Aged. Neoplasm Metastasis. Reproducibility of Results. Sensitivity and Specificity


47. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD: Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am J Obstet Gynecol; 2005 Apr;192(4):1230-7; discussion 1237-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
  • OBJECTIVE: This study was undertaken to report on the benign gynecologic conditions occurring among women with an intact uterus at enrollment in the Breast Cancer Prevention Trial of the National Surgical Adjuvant Breast and Bowel Project.
  • STUDY DESIGN: The incidence rates of several benign gynecologic conditions were determined and risks were compared among women receiving tamoxifen and those receiving placebo, based on risk ratios (RRs) with 95% CIs.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / therapy. Genital Diseases, Female / chemically induced. Genital Diseases, Female / pathology. Neoplasm Recurrence, Local / prevention & control. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Age Distribution. Aged. Chemotherapy, Adjuvant. Confidence Intervals. Dose-Response Relationship, Drug. Female. Humans. Incidence. Middle Aged. Neoplasm Staging. Probability. Reference Values. Risk Assessment

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Obstet Gynecol. 2006 Apr;194(4):1204-5; author reply 1205 [16580343.001]
  • (PMID = 15846210.001).
  • [ISSN] 0002-9378
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10-CA-37377; United States / NCI NIH HHS / CA / U10-CA-69974
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


48. Sohn V, Arthurs Z, Herbert G, Keylock J, Perry J, Eckert M, Fellabaum D, Smith D, Brown T: Atypical ductal hyperplasia: improved accuracy with the 11-gauge vacuum-assisted versus the 14-gauge core biopsy needle. Ann Surg Oncol; 2007 Sep;14(9):2497-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Percutaneous stereotactic core needle biopsy (CNB) has become the primary diagnostic modality for evaluating nonpalpable, mammographically detected breast lesions.
  • Mean number of passes obtained at time of biopsy, mean age of patients, and characteristic radiographic abnormalities were similar for malignant and benign diagnoses.
  • Surgical excision of ADH identified by CNB is required for definitive diagnosis.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Precancerous Conditions / pathology
  • [MeSH-minor] Female. Humans. Hyperplasia. Mammography. Middle Aged. Neoplasm Staging. Retrospective Studies. Vacuum

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17564749.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Cao D, Polyak K, Halushka MK, Nassar H, Kouprina N, Iacobuzio-Donahue C, Wu X, Sukumar S, Hicks J, De Marzo A, Argani P: Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res; 2008;10(5):R91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Although lobular carcinoma in situ (LCIS) has traditionally been viewed as a marker of breast cancer risk, recent clinical, pathological and genetic analyses have supported the concept that LCIS is a low risk, direct precursor of invasive lobular carcinoma.
  • By comparing the gene expression profile of LCIS to that of benign breast epithelium and stroma, we identified several genes up and down regulated in LCIS.
  • RESULTS: We identified down regulation of claudin 4 and overexpression of matrix metalloproteinase 9 in LCIS relative to normal breast epithelium and stroma.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 1999 Oct;189(2):161-8 [10547569.001]
  • [Cites] Histopathology. 2005 May;46(5):551-60 [15842637.001]
  • [Cites] Breast Cancer Res Treat. 2000 Aug;62(3):197-210 [11072784.001]
  • [Cites] Cancer Cell. 2004 Jul;6(1):17-32 [15261139.001]
  • [Cites] JAMA. 1967 Jul 10;201(2):82-6 [6072345.001]
  • [Cites] Mod Pathol. 2005 Jun;18(6):741-51 [15696125.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]
  • [Cites] Cancer. 2006 May 15;106(10):2104-12 [16604564.001]
  • [Cites] Adv Anat Pathol. 2006 Jul;13(4):157-65 [16858149.001]
  • [Cites] BMC Cancer. 2006;6:186 [16836752.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):427-37 [17325485.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):260-6 [17721269.001]
  • [Cites] Virchows Arch. 2007 Sep;451(3):669-80 [17609977.001]
  • [Cites] Am J Surg Pathol. 2008 Apr;32(4):513-23 [18223478.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4606-13 [18559505.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):5-7 [18598938.001]
  • [Cites] Hum Pathol. 2001 Mar;32(3):292-6 [11274638.001]
  • [Cites] Br J Cancer. 2001 Jun 1;84(11):1488-96 [11384099.001]
  • [Cites] Cancer Res. 2001 Jun 1;61(11):4320-4 [11389052.001]
  • [Cites] Int J Surg Pathol. 2001 Apr;9(2):127-31 [11484500.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):3862-8 [11751476.001]
  • [Cites] Lancet. 2003 Jan 11;361(9352):125-9 [12531579.001]
  • [Cites] Int J Cancer. 2003 Aug 20;106(2):208-15 [12800196.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):653-61 [12875984.001]
  • [Cites] Int J Cancer. 2003 Dec 20;107(6):970-5 [14601057.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):226-30 [14983936.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1627-33 [15111309.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2562-72 [15197797.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Cancer. 1974 Sep;34(3):554-63 [4853024.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1403-16 [8839545.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):297-301 [9149887.001]
  • [Cites] Br J Cancer. 1997;76(9):1131-3 [9365159.001]
  • [Cites] J Surg Oncol. 1998 Jan;67(1):41-6 [9457256.001]
  • [Cites] J Pathol. 1997 Dec;183(4):404-11 [9496256.001]
  • [Cites] Annu Rev Physiol. 1998;60:121-42 [9558457.001]
  • [Cites] Cancer Res. 1998 Jul 1;58(13):2876-80 [9661905.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4721-7 [9788628.001]
  • [Cites] Histopathology. 1999 Sep;35(3):195-200 [10469210.001]
  • [Cites] Semin Diagn Pathol. 1999 Aug;16(3):209-23 [10490198.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1531-6 [15619213.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):193-9 [15643498.001]
  • [Cites] Breast Cancer Res. 2005;7(2):R296-305 [15743508.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • (PMID = 18954444.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA088843; United States / NCI NIH HHS / CA / P50 CA88843
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN4 protein, human; 0 / Claudin-4; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ PMC2614499
  •  go-up   go-down


50. Jiang YX, Liu H, Liu JB, Zhu QL, Sun Q, Chang XY: Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol; 2007 Dec;33(12):1873-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound.
  • Accurate assessment of tumor size is necessary when selecting patients for breast-conserving surgery.
  • In the study of breast contrast-enhanced ultrasound (CEUS), we found that tumor size discrepancy between CEUS and conventional ultrasound (US) existed in some breast lesions, for which the reasons are not clear.
  • Breast CEUS examinations were performed in 104 patients with breast lesions.
  • The measurement of the 104 breast tumors on conventional US was obtained and compared with the measurement on CEUS.
  • A difference in measuring tumor size of >3 mm for tumors up to 1.7 cm and 4 mm for tumors >or=1.7 cm, was defined as a significant discrepancy between conventional US and CEUS.
  • The histopathological examination of size discrepancy was performed and the margin characteristics of breast cancers with larger measurements were compared with those with unchanged measurements.
  • Among the 104 lesions (43 malignant, 60 benign, 1 borderline), the size of 27 breast cancers and one granulomatous mastitis appeared larger at CEUS.
  • Pathologic examinations of the region corresponding to the measurement discrepancy were mainly ductal carcinomas in situ (DCIS), invasive carcinoma with a DCIS component, adenosis with lobular hyperplasia in breast cancers and inflammatory cell infiltration in one granulomatous mastitis.
  • Well-defined margin characteristics were significantly different between breast cancers with larger measurements at CEUS and those with unchanged measurements of size (p = 0.002), whereas no significant difference was found between the two groups in ill-defined, spiculated, hyperechoic halo, microlobulated and angulated margins (p = 0.463, 0.117, 0.194, 0.666 and 0.780, respectively).
  • This initial study suggests that significant discrepancy of breast lesion measurement between conventional US and CEUS is more likely presented in breast cancer than benign lesions.
  • The pathologic findings corresponding to the region of size increased at CEUS are malignant in most malignant lesions and benign in benign lesions.
  • It is difficult to predict whether the size measurement of the breast cancer increases at CEUS based on the margin characteristics showed on conventional US.
  • [MeSH-major] Breast Neoplasms / ultrasonography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Diseases / pathology. Breast Diseases / ultrasonography. Contrast Media. Female. Humans. Image Interpretation, Computer-Assisted / methods. Middle Aged. Neoplasm Staging. Phospholipids. Reproducibility of Results. Sulfur Hexafluoride

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. SULFUR HEXAFLUORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17686569.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Phospholipids; 0 / contrast agent BR1; WS7LR3I1D6 / Sulfur Hexafluoride
  •  go-up   go-down


51. Bleiweiss IJ, Nagi CS, Jaffer S: Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma. J Clin Oncol; 2006 May 1;24(13):2013-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Axillary sentinel lymph nodes can be falsely positive due to iatrogenic displacement and transport of benign epithelial cells in patients with breast carcinoma.
  • PURPOSE: Immunohistochemical (IHC) staining for cytokeratins (CK) is common practice in evaluating sentinel lymph nodes (SLNs) in patients with breast carcinoma.
  • Iatrogenic epithelial cell displacement and benign transport of breast epithelial cells into axillary lymph nodes are recently described phenomena.
  • We report 25 cases in which these factors probably resulted in benign epithelial cells in axillary SLNs (ie, false positivity).
  • METHODS: We reviewed 25 cases of CK-positive SLNs in which the epithelial cells had histologic and IHC characteristics different from their respective patients' underlying breast carcinomas.
  • RESULTS: In all cases, the cytologic features of the epithelial cells in the SLNs were benign, and 22 matched those of corresponding intraductal papillomas that were involved by or were separate from the DCIS in the original cores or surgical biopsies.
  • Nineteen cases showed benign epithelial cell displacement at the biopsy site.
  • Sentinel lymph nodes in breast carcinoma can be falsely positive.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Axilla. Cell Movement. Epithelial Cells / pathology. False Positive Reactions. Female. Humans. Immunohistochemistry. Keratins / analysis. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 May 1;24(13):1978-9 [16606969.001]
  • (PMID = 16606970.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


52. Swellam M, Arab LR, Bushnak HA: Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer. IUBMB Life; 2007 Jun;59(6):394-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical implications of HER-2/neu overexpression and proteolytic activity imbalance in breast cancer.
  • The aggressive biological behavior of invasive and metastatic cancer is considered to be the most insidious and life-threatening aspect for breast cancer patients.
  • It is mostly the result of changes in many molecular characteristics of tumor cells, including alterations in gene expression and the balance of proteolytic activity.
  • Markers were analyzed in 240 tissue samples categorized into 96 benign breast disease and 144 breast cancer patients.
  • Breast cancer patients were followed-up for three years.
  • Positive values for all investigated factors were significantly increased in breast cancer patients compared to benign ones.
  • Mean levels for all investigated factors were significantly correlated with lymph node and hormone receptor status, while MMP-2 and TIMP-2 were correlated with tumor grade (P < 0.05).
  • In Univariate analysis, positive MMP-2, MMP-2/TIMP-2, HER-2/neu overexpression, higher tumor grade, late clinical stages and positive lymph nodes status were significantly associated with relapse.
  • By multivariate analysis, all aforementioned factors apart from tumor grade were independent variables.
  • Thus, the investigated markers are constructive for biologic aggressiveness of breast cancer and MMP-2/TIMP-2 ratio might be a new significant marker in early diagnosis and estimate prognosis in breast cancer.
  • [MeSH-major] Breast Neoplasms. Matrix Metalloproteinase 2 / metabolism. Receptor, ErbB-2 / metabolism. Tissue Inhibitor of Metalloproteinase-2 / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Staging. Prognosis. Reproducibility of Results. Survival Rate

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613170.001).
  • [ISSN] 1521-6543
  • [Journal-full-title] IUBMB life
  • [ISO-abbreviation] IUBMB Life
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 2.7.10.1 / Receptor, ErbB-2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


53. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, Lazar V, Lacroix L, Vassal G, Spielmann M, Vielh P, Delaloge S: Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol; 2009 Apr;10(4):381-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis.
  • BACKGROUND: Gene-expression arrays have generated molecular predictors of relapse and drug sensitivity in breast cancer.
  • We aimed to identify exons differently expressed in malignant and benign breast lesions and to generate a molecular classifier for breast-cancer diagnosis.
  • METHODS: 165 breast samples were obtained by fine-needle aspiration.
  • A nearest centroid prediction rule was developed to classify lesions as malignant or benign on a training set, and its performance was assessed on an independent validation set.
  • A two-way ANOVA model identified probe sets with differential expression in malignant and benign lesions while adjusting for scan dates.
  • FINDINGS: 120 breast cancers and 45 benign lesions were included in the study.
  • A molecular classifier for breast-cancer diagnosis with 1228 probe sets was generated from the training set (n=94).
  • When the 165 samples were taken into account, 37 858 exon probe sets (5.4%) and 3733 genes (7.0%) were differently expressed in malignant and benign lesions (threshold: adjusted p<0.05).
  • In the same population of 165 samples, 956 exon probe sets presented both higher intensity and higher splice index in breast cancer than in benign lesions, although located on unchanged genes.
  • INTERPRETATION: Many exons are differently expressed by breast cancer and benign lesions, and alternative transcripts contribute to the molecular characteristics of breast malignancy.
  • Development of molecular classifiers for breast-cancer diagnosis with fine-needle aspiration should be possible.
  • [MeSH-major] Breast Neoplasms / genetics. Exons / genetics. Gene Expression Profiling. Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / genetics. Carcinoma, Ductal, Breast / secondary. Carcinoma, Intraductal, Noninfiltrating / drug therapy. Carcinoma, Intraductal, Noninfiltrating / genetics. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Carcinoma, Lobular / secondary. Carcinoma, Papillary / drug therapy. Carcinoma, Papillary / genetics. Carcinoma, Papillary / secondary. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Prognosis. RNA Splicing / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome. Validation Studies as Topic. Young Adult

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet Oncol. 2009 Apr;10(4):314-5 [19341968.001]
  • (PMID = 19249242.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger
  •  go-up   go-down


54. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Archival paraffin-embedded cell blocks of serous fluids from 28 cases of reactive mesothelial cells, 14 cases of MM, 20 cases of metastatic ovarian carcinomas, 17 cases of metastatic breast carcinomas, 12 cases of metastatic lung ACA, and 12 cases of metastatic gastrointestinal ACA were stained with HA using a biotinylated HABP and CD44S.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44S was expressed in 100% (28/28) of mesothelial hyperplesia, 86% (12/14) of MMs, 70% (14/20) of ovarian carcinomas, 29% (5/17) of breast carcinomas, 25% (3/12) of gastrointestinal ACAs, and 8% (1/12) of lung ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


55. Esposito NN, Mohan D, Brufsky A, Lin Y, Kapali M, Dabbs DJ: Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. Arch Pathol Lab Med; 2006 Oct;130(10):1516-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases.
  • CONTEXT: Phyllodes tumors (PTs) of the breast are biphasic neoplasms composed of epithelium and a spindle-cell stroma.
  • Currently, PTs are classified as benign, borderline, or malignant based on histopathologic features.
  • DESIGN: Sixteen benign, 8 borderline, and 6 malignant PTs with follow-up were examined for reactivity across a panel of immunohistochemical stains, including c-Kit, endothelin 1, p16, p21, p53, and Ki-67.
  • Tumor variables were compared among tumor subgroups and between tumors that did and did not recur.
  • RESULTS: Of the 30 PTs, 4 recurred (1 benign, 2 borderline, 1 malignant).
  • One patient with a malignant tumor died of metastatic disease 34 months after initial diagnosis.
  • The overall positive rate of c-Kit immunoreactivity was 13% in benign, 63% in borderline, and 67% in malignant PTs.
  • Endothelin 1 epithelial cytoplasmic staining was seen in 100% of benign, 50% of borderline, and 17% of malignant PTs.
  • Additionally, p16, p21, p53, and Ki-67 were differentially expressed among benign, borderline, and malignant tumors.
  • CONCLUSIONS: Stromal c-Kit positivity and epithelial endothelin 1 negativity are more often associated with malignant PTs; however, only positive margin status is significantly associated with tumor behavior.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Phyllodes Tumor / metabolism. Phyllodes Tumor / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Disease Progression. Endothelin-1 / metabolism. Epithelium / metabolism. Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. Mastectomy. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proto-Oncogene Proteins c-kit / metabolism. Staining and Labeling. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090194.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Endothelin-1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


61. Zissimopoulos A, Stellos K, Matthaios D, Petrakis G, Parmenopoulou V, Babatsikou F, Matthaiou E, Theodosiadou E, Hountis P, Koutis C: Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy. J BUON; 2009 Jul-Sep;14(3):463-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
  • PURPOSE: In this study we evaluated the clinical usefulness of serum pro-I collagen peptide (PICP) and I collagen telopeptide (ICTP) as indicators of early bone metastases in patients with breast (BC), lung (LC), urinary bladder (UBC) and prostate cancer (PC).
  • ICTP and CA 15-3 were the most reliable markers for early diagnosis of bone metastases in BC.
  • Furthermore, PICP and PSA levels were significantly higher in patients with PC and bone metastases in comparison to patients with benign prostate hyperplasia (BPH) (p <0.0001) or in patients with PC without bone metastases (p <0.0005 for PICP and p <0.0001 for PSA).
  • CONCLUSION: ICTP and CA 15-3 are the most reliable markers for early diagnosis of bone metastases in BC patients.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Bone Neoplasms / diagnosis. Bone Neoplasms / secondary. Collagen Type I / metabolism
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / pathology. Carcinoembryonic Antigen / metabolism. Female. Humans. Immunoradiometric Assay. Lung Neoplasms / pathology. Male. Middle Aged. Mucin-1 / metabolism. Neoplasm Metastasis. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / pathology. Sensitivity and Specificity. Tomography, Emission-Computed. Urinary Bladder Neoplasms / pathology


62. Neagu A, Muscă S, Slătineanu S, Pricop M: [Breast conservative surgery]. Rev Med Chir Soc Med Nat Iasi; 2005 Jan-Mar;109(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast conservative surgery].
  • Breast conservative therapy is considered an adequate therapeutical method for early stage breast cancer.
  • Breast conservative treatment consists of partial mastectomy, axillary dissection and radiotherapy.
  • The frozen sections examination provides prompt differentiation between benign/malign lesions and precise assessment of the oncologic margins of the specimen.
  • Preoperative marking of nonpalpable breast lesion with hook wire represents a progress for breast conservative treatment.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy, Segmental / methods
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Radiotherapy, Adjuvant. Sentinel Lymph Node Biopsy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16607830.001).
  • [ISSN] 0048-7848
  • [Journal-full-title] Revista medico-chirurgicală̆ a Societă̆ţ̜ii de Medici ş̧i Naturaliş̧ti din Iaş̧i
  • [ISO-abbreviation] Rev Med Chir Soc Med Nat Iasi
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Romania
  • [Number-of-references] 18
  •  go-up   go-down


63. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer; 2005 May 1;103(9):1778-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: During a review of 1877 breast biopsy specimens in a nested case-control study of benign breast disease and breast carcinoma risk, the authors identified 13 biopsy specimens with DCIS that were originally diagnosed as benign.
  • Because each of these women was initially given a benign diagnosis, they received no treatment beyond the diagnostic biopsy.
  • RESULTS: When compared with women with nonproliferative lesions, the odds ratio (OR) for the development of invasive breast carcinoma among those with retrospectively identified DCIS (n = 6) was 13.5 (95% confidence interval [CI], 3.7-49.7).
  • The OR for the development of any subsequent invasive or in situ breast carcinoma event (n = 10) was 20.1 (95% CI, 6.1-66. 5).
  • All 10 breast carcinoma events (100%) were in the ipsilateral breast.
  • CONCLUSIONS: These results provided further evidence that patients with DCIS who received no treatment beyond a diagnostic biopsy were at substantially increased risk for developing ipsilateral invasive breast carcinoma, and that the increased risk in this setting was seen in DCIS of low, intermediate, and high nuclear grades.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Ductal, Breast / diagnosis
  • [MeSH-minor] Adult. Biopsy. Case-Control Studies. Cell Nucleus / pathology. Cohort Studies. Female. Humans. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasms / diagnosis. Neoplasms / therapy. Retrospective Studies. Risk Factors. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15770688.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA046475; United States / NCI NIH HHS / CA / CA050385; United States / NCI NIH HHS / CA / CA087969
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


64. Abdalla FB, Boder JM, Buhmeida A, Elzagheid AI, Collan Y: Image DNA cytometry in FNABs of Libyan breast disease. Anticancer Res; 2010 Jan;30(1):175-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image DNA cytometry in FNABs of Libyan breast disease.
  • This percentage is dependent on the number of examined cells, type of breast cancer, and experience of the examiner.
  • The aim of our study was to estimate the supporting value of image DNA cytometry of FNAB of the breast, and do so by using different sampling methods.
  • MATERIALS AND METHODS: This retrospective study was based on 41 cases with an available histological diagnosis: 18 benign lesions and 23 malignant tumours were examined.
  • The method can be used to increase the cytological sensitivity and specificity in doubtful breast lesions.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. DNA, Neoplasm / analysis. Image Cytometry / methods
  • [MeSH-minor] Aneuploidy. Biopsy, Fine-Needle / methods. Female. Humans. Libya. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150633.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


65. Grabiec M, Nowicki P, Walentowicz M, Greźlikowska U, Mierzwa T, Chmielewska W: [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients]. Ginekol Pol; 2005 May;76(5):371-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of Ca-125 in the differential diagnosis of adnexal mass in breast cancer patients].
  • OBJECTIVES: Serum CA-125 is of value in differential diagnosis of benign and malignant adnexal masses, especially in postmenopausal women.
  • In ovarian cancer preoperative CA-125 levels are related to tumor stage, histologic grade, but are not an independent prognostic factor.
  • DESIGN: The aim of our study was to determine CA-125 serum level in women with ovarian tumor treated previously because of breast cancer.
  • All those patients were treated because of breast cancer previously.
  • RESULTS: In 19 women (37,3%) benign ovarian tumors were found, in 4 cases (7,8) - primary ovarian cancer whereas in 28 patients (54,9%) breast cancer metastases were detected.
  • 2. In a group of women with breast cancer and ovarian tumor, metastatic adnexal masses were observed in more than 50% of cases.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / pathology. CA-125 Antigen / blood. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Poland. Preoperative Care / methods. Retrospective Studies. Risk Assessment. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145856.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


66. Byrne JA, Balleine RL, Schoenberg Fejzo M, Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K, Karlan BY, Slamon DJ, Harnett P, Defazio A: Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Int J Cancer; 2005 Dec 20;117(6):1049-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
  • Since tumor protein D52 (TPD52) has been identified as a chromosome 8q21 amplification target in breast and prostate carcinoma, we compared TPD52 expression in normal ovarian epithelium (n = 9), benign serous adenomas (n = 11), serous borderline tumors (n = 6) and invasive carcinomas of the major histologic subtypes (n = 57) using immunohistochemistry.
  • These analyses revealed that all normal ovarian epithelium samples and benign serous tumors were predominantly TPD52-negative, whereas TPD52 was overexpressed in most (44/57; 77%) ovarian carcinomas regardless of histologic subtype.
  • [MeSH-major] Gene Amplification / genetics. Gene Expression. Neoplasm Proteins / genetics. Ovarian Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. CA-125 Antigen / blood. Chromosomes, Human, Pair 8. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Middle Aged. Ovary / chemistry

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc
  • (PMID = 15986428.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Neoplasm Proteins; 0 / TPD52 protein, human
  •  go-up   go-down


67. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V: Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology; 2008 Jun;247(3):651-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer.
  • PURPOSE: To retrospectively determine the sensitivity and specificity of breast-specific gamma imaging (BSGI) for the detection of breast cancer by using pathologic results as the reference standard.
  • A retrospective review of 146 women (aged 32-98 years) undergoing BSGI and breast biopsy was performed.
  • Of 84 nonmalignant lesions, 82 were benign and two showed atypical histologic results (one atypical lobular hyperplasia and one lobular carcinoma in situ).
  • CONCLUSION: BSIG has high sensitivity (96.4%) and moderate specificity (59.5%) helping detect breast cancers.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Carcinoma, Ductal, Breast / radionuclide imaging. Gamma Cameras
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity. Technetium Tc 99m Sestamibi

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2008.
  • [CommentIn] Radiology. 2009 Apr;251(1):306; author reply 306 [19332861.001]
  • [ErratumIn] Radiology. 2009 Apr;251(1):308
  • (PMID = 18487533.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 971Z4W1S09 / Technetium Tc 99m Sestamibi
  •  go-up   go-down


68. Colombo P, Tondulli L, Masci G, Muzza A, Rimassa L, Petrella D, Santoro A: Oral ulcer as an exclusive sign of gastric cancer: report of a rare case. BMC Cancer; 2005;5:117
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The oral cavity is a rare but occasional target for metastases, which may masquerade as various benign and inflammatory lesions, and sometimes also be asymptomatic.
  • Oral metastatic lesions have been described in various cancers, particularly lung, breast and kidney carcinoma.
  • The patient underwent gastric resection but died of heart failure on the tenth postoperative day; a post-mortem examination revealed a residual bilateral ovarian infiltration by gastric carcinoma (Krukenberg's tumor).
  • CONCLUSION: An occult carcinoma of the stomach may rarely metastasise to the oral cavity even as a first and exclusive manifestation; it is important to bear this possibility in mind because such conditions may mimic a benign disease.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / pathology. Gingival Neoplasms / secondary. Mouth / pathology. Mouth Neoplasms / secondary. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology. Ulcer / pathology
  • [MeSH-minor] Biopsy. Carcinoma / pathology. Cell Differentiation. Fatal Outcome. Female. Humans. Immunohistochemistry. Middle Aged. Mouth Mucosa / pathology. Neoplasm Metastasis. Palate, Hard / pathology

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Periodontol. 1976 Jun;47(6):358-60 [1064724.001]
  • [Cites] Rev Clin Esp. 1989 Jan;184(1):52-3 [2704876.001]
  • [Cites] Cancer. 1993 Jun 1;71(11):3472-7 [8387879.001]
  • [Cites] J Oral Maxillofac Surg. 1995 Sep;53(9):1097-8 [7643282.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 Nov;31B(6):355-60 [8746264.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1973 Oct;36(4):544-50 [4580924.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2237-46 [11147594.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):831-5 [15209637.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1968 Jun;25(6):805-9 [5239733.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1969 Dec;28(6):859-61 [5260657.001]
  • [Cites] Cancer. 1998 Nov 15;83(10):2049-53 [9827707.001]
  • (PMID = 16171522.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1242220
  •  go-up   go-down


69. Chung A, Yu J, Stempel M, Patil S, Cody H, Montgomery L: Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients? Ann Surg Oncol; 2008 Oct;15(10):2728-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is the "10% rule" equally valid for all subsets of sentinel-node-positive breast cancer patients?
  • BACKGROUND: In breast cancer, a combination of radioisotope and blue dye mapping maximizes the success and accuracy of sentinel node (SLN) biopsy.
  • METHODS: Between 9/96 and 12/04, we performed 6,369 successful SLN biopsies using (99m)Tc sulfur colloid and isosulfan blue dye, removing as SLN all radioactive and/or blue nodes, and taking counts from each node ex vivo.
  • Standard processing of all SLNs with a benign frozen section included hematoxylin and eosin (H&E) staining, serial sectioning, and immunohistochemistry (IHC).
  • The most radioactive SLN was benign in 29% (398/1,387), and 107/1,387 (8%) had a positive SLN that was neither blue nor the hottest.
  • [MeSH-major] Breast Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / radionuclide imaging. Carcinoma, Intraductal, Noninfiltrating / secondary. Carcinoma, Lobular / radionuclide imaging. Carcinoma, Lobular / secondary. Coloring Agents. Female. Humans. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Prospective Studies. Radiopharmaceuticals. Retrospective Studies. Rosaniline Dyes. Sentinel Lymph Node Biopsy. Technetium Tc 99m Sulfur Colloid

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Isosulfan blue .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18688679.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Radiopharmaceuticals; 0 / Rosaniline Dyes; 39N9K8S2A4 / iso-sulfan blue; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


70. Nga ME, Lim KH, Tan EY, Chan P, Tan SY, Walford N: Malignant adenomyoepithelial tumor of the breast: multi-immunolabeling technique and detailed immunophenotypic study. Appl Immunohistochem Mol Morphol; 2008 Jan;16(1):100-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant adenomyoepithelial tumor of the breast: multi-immunolabeling technique and detailed immunophenotypic study.
  • Biphasic ductal and myoepithelial lesions of the breast are uncommon.
  • A majority of these rare lesions behave in a benign fashion.
  • In addition, we apply the relatively novel technique of multi-immunolabeling combined with Adobe Photoshop imaging to highlight the different components of the neoplasm on the same tissue section.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18091311.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 68238-35-7 / Keratins
  •  go-up   go-down


71. Guttery DS, Hancox RA, Mulligan KT, Hughes S, Lambe SM, Pringle JH, Walker RA, Jones JL, Shaw JA: Association of invasion-promoting tenascin-C additional domains with breast cancers in young women. Breast Cancer Res; 2010;12(4):R57
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of invasion-promoting tenascin-C additional domains with breast cancers in young women.
  • The profile of isoforms expressed differs between cancers and normal breast, with the two additional domains AD1 and AD2 considered to be tumour associated.
  • The aim of the present study was to investigate expression of AD1 and AD2 in normal, benign and malignant breast tissue to determine their relationship with tumour characteristics and to perform in vitro functional assays to investigate the role of AD1 in tumour cell invasion and growth.
  • METHODS: Expression of AD1 and AD2 was related to hypoxanthine phosphoribosyltransferase 1 as a housekeeping gene in breast tissue using quantitative RT-PCR, and the results were related to clinicopathological features of the tumours.
  • Constructs overexpressing an AD1-containing isoform (TNC-14/AD1/16) were transiently transfected into breast carcinoma cell lines (MCF-7, T-47 D, ZR-75-1, MDA-MB-231 and GI-101) to assess the effect in vitro on invasion and growth.
  • RESULTS: Quantitative RT-PCR detected AD1 and AD2 mRNA expression in 34.9% and 23.1% of 134 invasive breast carcinomas, respectively.
  • AD1 mRNA was localised by in situ hybridisation to tumour epithelial cells, and more predominantly to myoepithelium around associated normal breast ducts.
  • CONCLUSIONS: Together these data suggest a highly significant association between AD-containing TNC isoforms and breast cancers in younger women (age ≤40 years), which may have important functional significance in vivo.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 2000 Jan;105(1):21-34 [10619858.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1796-800 [8956795.001]
  • [Cites] Matrix Biol. 2000 Dec;19(7):581-96 [11102748.001]
  • [Cites] Lancet. 2001 Jun 23;357(9273):1992-4 [11438127.001]
  • [Cites] Cell Struct Funct. 2001 Jun;26(3):179-87 [11565810.001]
  • [Cites] Int J Cancer. 2002 Mar 10;98(2):205-9 [11857409.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1152-6 [11948127.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):97-104 [12027581.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3289-97 [12036947.001]
  • [Cites] Eur J Cancer. 2002 Dec;38(18):2362-70 [12460779.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1857-67 [12759243.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):8-16 [12794751.001]
  • [Cites] J Pathol. 2003 Dec;201(4):562-72 [14648659.001]
  • [Cites] Science. 2004 Feb 6;303(5659):775-7 [14764858.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7377-85 [15492259.001]
  • [Cites] N Engl J Med. 1986 Aug 28;315(9):559-63 [3736639.001]
  • [Cites] J Cell Biol. 1991 Nov;115(4):1127-36 [1720121.001]
  • [Cites] J Cell Physiol. 1992 Mar;150(3):534-44 [1537883.001]
  • [Cites] Lancet. 1992 Jun 13;339(8807):1483 [1351156.001]
  • [Cites] Cancer Res. 1992 Oct 1;52(19):5190-7 [1382837.001]
  • [Cites] Int J Cancer. 1992 Nov 11;52(5):688-92 [1385335.001]
  • [Cites] Nucleic Acids Res. 1993 Jan 11;21(1):163-8 [7680113.001]
  • [Cites] Lancet. 1993 Apr 24;341(8852):1039-43 [8096955.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):10154-8 [7694284.001]
  • [Cites] Development. 1994 Mar;120(3):637-47 [7512896.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):539-48 [7518469.001]
  • [Cites] Mol Biol Cell. 1994 Apr;5(4):439-53 [7519905.001]
  • [Cites] FEBS Lett. 1994 Sep 26;352(2):216-8 [7523186.001]
  • [Cites] J Biol Chem. 1995 Apr 14;270(15):8650-4 [7536739.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):97-103 [8630946.001]
  • [Cites] FEBS Lett. 1996 Jul 8;389(3):304-8 [8766721.001]
  • [Cites] Mol Biol Cell. 1996 Jun;7(6):883-92 [8816995.001]
  • [Cites] Br J Cancer. 1996 Oct;74(7):999-1004 [8855965.001]
  • [Cites] Int J Cancer. 1997 Jul 17;72(2):236-40 [9219826.001]
  • [Cites] Differentiation. 1997 Nov;62(2):71-82 [9404002.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1095-104 [9512505.001]
  • [Cites] Invest Ophthalmol Vis Sci. 1998 Jun;39(7):1135-42 [9620072.001]
  • [Cites] Br J Cancer. 1998 Dec;78(11):1507-13 [9836485.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1345-52 [10329587.001]
  • [Cites] Int J Cancer. 1999 Aug 12;82(4):477-83 [10404058.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Mol Biol Cell. 1999 Sep;10(9):2933-43 [10473637.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4003-11 [15930334.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5175-80 [16033833.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3200-8 [16707621.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Cell. 2006 Dec;10(6):515-27 [17157791.001]
  • [Cites] Histopathology. 2007 Mar;50(4):434-8 [17448018.001]
  • [Cites] Mol Biol Cell. 2007 Nov;18(11):4615-24 [17855508.001]
  • [Cites] J Biol Chem. 2007 Nov 30;282(48):34929-37 [17901052.001]
  • [Cites] Breast Cancer Res. 2007;9(6):404; author reply 405 [18279542.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1368-76 [18316557.001]
  • [Cites] Cancer Res. 2008 Sep 1;68(17):6942-52 [18757408.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5555-64 [18765548.001]
  • [Cites] Breast Cancer Res. 2009;11(2):R24 [19405959.001]
  • [Cites] J Vis Exp. 2009;(29). pii: 1475. doi: 10.3791/1475 [19620957.001]
  • [Cites] J Pathol. 1999 Dec;189(4):475-80 [10629546.001]
  • (PMID = 20678196.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / Tenascin
  • [Other-IDs] NLM/ PMC2949648
  •  go-up   go-down


72. Houssami N, Ciatto S, Ellis I, Ambrogetti D: Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates. Cancer; 2007 Feb 1;109(3):487-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Underestimation of malignancy of breast core-needle biopsy: concepts and precise overall and category-specific estimates.
  • BACKGROUND: A review of the literature indicated variable underestimation rates for breast core-needle biopsy (CNB) based on generally small series.
  • METHODS: Among 4035 consecutive CNBs, the authors examined women whose CNB outcome represented a potential underestimate of malignancy (benign but of uncertain biologic or malignant potential or B3 and ductal carcinoma in situ [DCIS]).
  • The following category-specific rates were used: B3 underestimates, 36.2% (95% CI, 30.6-41.8%); B3 underestimates (excluding atypical proliferations), 17.9% (95% CI, 10.8-24.9%); atypical ductal hyperplasia underestimates, 29.0% (95% CI, 21.4-36.6%; upgraded to DCIS) and 44.2% (95% CI, 36.0-52.5%; upgraded to DCIS or invasive cancer); and DCIS underestimates, 22.8% (95% CI, 19.0-26.5%).
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma, Ductal, Breast / diagnosis. Carcinoma, Intraductal, Noninfiltrating / diagnosis
  • [MeSH-minor] Biopsy, Fine-Needle. Female. Humans. Hyperplasia / diagnosis. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • [CommentIn] Cancer. 2007 Jul 15;110(2):465-6; author reply 466 [17520669.001]
  • (PMID = 17186530.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Tan JM, Ng EY, Acharya RU, Keith LG, Holmes J: Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data. J Med Syst; 2009 Apr;33(2):141-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative study on the use of analytical software to identify the different stages of breast cancer using discrete temperature data.
  • Breast cancer is the second leading cause of death in women.
  • It occurs when cells in the breast begin to grow out of control and invade nearby tissues or spread throughout the body.
  • The aim of this study was to develop a feasible interpretive software system which was able to detect and classify breast cancer patients by employing techniques of different analytical software.
  • The protocol described uses 6,000 pieces of thermal data collected from 16-sensors, eight placed on the surface of each breast.
  • Placement of sensors was accomplished with the use of a template design from information provided by the national tumor registry to insure that the information was collected in areas of the breast where most breast cancers develop.
  • Data in this study was collected from 90 individuals exhibiting four different breast conditions, namely: normal, benign, cancer and suspected-cancer.
  • The temperature data collected from these 16 sensors placed on the surface of each breast were fed as inputs to the classifiers.
  • These classifiers were able to attain approximately 80% accuracy in classifying the four different diagnoses (normal, benign, cancer and suspected-cancer).
  • Based on these evaluations, this current effort shows the feasibility of applying analytical software techniques together with the real-time functional thermal analysis to develop a potential tool for the detection and classification of breast cancer.
  • [MeSH-major] Body Temperature / physiology. Breast Neoplasms / pathology. Signal Processing, Computer-Assisted / instrumentation. Software. Thermography / methods
  • [MeSH-minor] Algorithms. Data Interpretation, Statistical. Female. Fuzzy Logic. Humans. Image Interpretation, Computer-Assisted. Neoplasm Staging. Neural Networks (Computer). Normal Distribution. ROC Curve. User-Computer Interface

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2007 Mar 29;356(13):1295-303 [17392300.001]
  • [Cites] IEEE Trans Neural Netw. 2001;12(2):181-201 [18244377.001]
  • [Cites] N Engl J Med. 2004 Jul 29;351(5):427-37 [15282350.001]
  • [Cites] Cancer. 2005 May 1;103(9):1898-905 [15800894.001]
  • [Cites] Int J Fertil Womens Med. 2005 Sep-Oct;50(5 Pt 1):199-206 [16468469.001]
  • [Cites] JAMA. 2004 Sep 15;292(11):1317-25 [15367553.001]
  • [Cites] Am J Surg. 2005 Oct;190(4):572-5 [16164923.001]
  • [Cites] Int Semin Surg Oncol. 2006 Apr 03;3:8 [16584542.001]
  • [Cites] J Med Eng Technol. 2002 Jul-Aug;26(4):152-7 [12396330.001]
  • [Cites] Bull World Health Organ. 1970;43(2):209-21 [5312521.001]
  • [Cites] Breast Cancer Res Treat. 1996;37(1):1-9 [8750522.001]
  • [Cites] Int Semin Surg Oncol. 2005 Apr 08;2(1):8 [15819982.001]
  • [Cites] Cancer. 1994 Jul 1;74(1 Suppl):244-55 [8004594.001]
  • [Cites] Int J Fertil Womens Med. 2001 Sep-Oct;46(5):238-47 [11720196.001]
  • [Cites] IEEE Trans Neural Netw. 2002;13(2):415-25 [18244442.001]
  • [Cites] Bibl Radiol. 1975;(6):77-90 [1180864.001]
  • (PMID = 19397099.001).
  • [ISSN] 0148-5598
  • [Journal-full-title] Journal of medical systems
  • [ISO-abbreviation] J Med Syst
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Zhu W, Qin W, Bradley P, Wessel A, Puckett CL, Sauter ER: Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid. Carcinogenesis; 2005 Jan;26(1):145-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitochondrial DNA mutations in breast cancer tissue and in matched nipple aspirate fluid.
  • The aims of this study were to (i) determine the mutation patterns of breast cancers through a comprehensive screen of mtDNA mutations, and (ii) assess if mutations in the cancers are also detectable in breast nipple aspirate fluid (NAF), a physiologic fluid which contains shed ductal epithelial cells.
  • Fifteen breast cancers, matched benign tissues and NAF were collected.
  • In conclusion, mtDNA mutations in breast cancer occur both within and outside of the D-loop, though the mutation rate in the D-loop is over 7-fold higher than in coding areas.
  • Specific mtDNA mutations can be detected in a subset of NAF samples from women with breast cancer.
  • [MeSH-major] Body Fluids / physiology. Breast Neoplasms / genetics. DNA, Mitochondrial / genetics. DNA, Neoplasm / genetics. Nipples / metabolism
  • [MeSH-minor] Base Sequence. DNA Mutational Analysis. Female. Humans. Molecular Sequence Data. Mutation. Polymerase Chain Reaction. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15375011.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Mitochondrial; 0 / DNA, Neoplasm
  •  go-up   go-down


75. Yang HW, Cao J, Yang NW, Liu JL, Zhang CM, Chen JS, Hong JS, Jiang Y, Su JJ: [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance]. Ai Zheng; 2005 Jul;24(7):842-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of small breast epithelial mucin mRNA in peripheral blood of breast cancer patients and its clinical significance].
  • BACKGROUND & OBJECTIVE: The major cause of death in breast cancer patients is distant metastasis.
  • This study was to explore the expression and significance of small breast epithelial mucin (SBEM) mRNA, the specific marker of breast cancer, in peripheral blood of breast cancer patients.
  • METHODS: Expression of SBEM mRNA in peripheral blood samples from 67 breast cancer patients, 16 benign breast disease patients, and 20 healthy volunteers was detected by nested reverse transcription-polymerase chain reaction (nested RT-PCR).
  • RESULTS: SBEM mRNA was not detected in healthy volunteers and benign breast disease patients.
  • Positive rate of SBEM mRNA was 50.7% (34/67) in breast cancer patients.
  • The expression of SBEM mRNA in peripheral blood was not correlated with patient's age, primary tumor size, pathologic type, and estrogen or progestin receptor status (P0.05).
  • CONCLUSION: SBEM mRNA is specifically expressed in peripheral blood of breast cancer patients, and may be a marker of micrometastasis of breast cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Breast Neoplasms / metabolism. Carcinoma, Ductal, Breast / metabolism. Mucins / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Female. Fibroma / metabolism. Fibroma / pathology. Humans. Middle Aged. Neoplasm Staging. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Estrogen / blood. Receptors, Progesterone / blood

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16004812.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUCL1 protein, human; 0 / Mucins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


76. Cusumano P, Polkowski WP, Liu H, Schulz-Wendtland R, Janssens J: Percutaneous tissue acquisition: a treatment for breast cancer? Vacuum-assisted biopsy devices are not indicated for extended tissue removal. Eur J Cancer Prev; 2008 Aug;17(4):323-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous tissue acquisition: a treatment for breast cancer? Vacuum-assisted biopsy devices are not indicated for extended tissue removal.
  • Quite a number of radiologists indicate that complete removal of an imaged lesion in the breast by transdermal tissue acquisition is beneficial for the patient.
  • In addition, there is no evidence that complete removal of benign lesions is good for the patient.
  • When benign lesions can be considered precursors for malignancy, they should be surgically removed as for other premalignant lesions.
  • Most benign lesions can be treated medically as they are usually dispersed in the breast and hormone dependent.
  • The rest of benign breast lesions need removal only to relieve the patient of psychological stress or because of symptoms.
  • Evidence indicates furthermore that increase in cancer risk is related to the number and extent of breast interventions in the past.
  • VAB and other large core biopsy devices remain a useful tool in the diagnosis of breast cancer but not for treatment purposes.
  • [MeSH-major] Biopsy, Needle / adverse effects. Biopsy, Needle / instrumentation. Breast Neoplasms / pathology. Neoplasm Invasiveness / prevention & control. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Mastectomy / methods. Middle Aged. Neoplasm Staging. Reproducibility of Results. Risk Assessment. Sensitivity and Specificity. Vacuum

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18562956.001).
  • [ISSN] 1473-5709
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 36
  •  go-up   go-down


77. De Cesare A, Fiori E, Burza A, Ciardi A, Bononi M, Izzo L, Volpino P, Cavallaro A, Cangemi V: Malignant fibrous histiocytoma of the breast. Report of two cases and review of the literature. Anticancer Res; 2005 Jan-Feb;25(1B):505-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant fibrous histiocytoma of the breast. Report of two cases and review of the literature.
  • Sarcomas of the breast are uncommon, accounting for less than 1% of all primary malignancies.
  • Two cases of this neoplasm are reported, with histological findings and surgical treatment.
  • The issue of radiation-induced lesions after surgery for carcinoma and the necessity for a correct preoperative diagnosis is examined.
  • A review of the available literature evaluates the histopathological and biological features of MFH of the breast, for which there are no prospective trials, owing to the rarity of this kind of neoplasm.
  • [MeSH-major] Breast Neoplasms / diagnosis. Histiocytoma, Benign Fibrous / diagnosis
  • [MeSH-minor] Adult. Aged. Breast / pathology. Female. Fibroblasts / metabolism. Humans. Immunohistochemistry. Lymphatic Metastasis. Mammography. Time Factors

  • Genetic Alliance. consumer health - Malignant fibrous histiocytoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816619.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


78. Schiffhauer LM, Boger JN, Bonfiglio TA, Zavislan JM, Zuley M, Fox CA: Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections. BMC Cancer; 2009;9:265
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Confocal microscopy of unfixed breast needle core biopsies: a comparison to fixed and stained sections.
  • BACKGROUND: Needle core biopsy, often in conjunction with ultrasonic or stereotactic guided techniques, is frequently used to diagnose breast carcinoma in women.
  • This paper reports the progress in developing techniques to rapidly screen needle core breast biopsy and surgical specimens at the point of care.
  • CSLM requires minimal tissue processing and has the potential to reduce the time from excision to diagnosis.
  • METHODS: Needle core breast specimens from 49 patients were imaged at the time of biopsy.
  • These lesions had been characterized under the Breast Imaging Reporting And Data System (BI-RADS) as category 3, 4 or 5.
  • Immediately following imaging, the specimens were fixed in buffered formalin and submitted for histological processing and pathological diagnosis.
  • RESULTS: The pathologic diagnoses by standard histology were 7 invasive ductal carcinomas, 2 invasive lobular carcinomas, 3 ductal carcinomas in-situ (CIS), 21 fibrocystic changes/proliferative conditions, 9 fibroadenomas, and 5 other/benign; two were excluded due to imaging difficulties.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images and were comparable to standard histologic sections of the same tissue.
  • Morphologic and cellular features of benign and cancerous lesions were identified in the confocal images.
  • Additional studies are needed to 1.) establish correlation of the confocal and traditional histologic images for the various diseases of the breast; 2.) validate diagnostic use of CSLM and; 3.) further define features of borderline lesions such as well-differentiated ductal CIS vs. atypical hyperplasia.
  • [MeSH-major] Biopsy, Needle / methods. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Microscopy, Confocal / methods
  • [MeSH-minor] Biopsy. Cell Proliferation. Contrast Media / pharmacology. Female. Humans. Medical Oncology / methods. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Oct;33(10):975-82 [12395369.001]
  • [Cites] Pancreatology. 2001;1(1):48-57 [12120268.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1137-43 [11710924.001]
  • [Cites] Surgery. 2000 Dec;128(6):1088-1100; discussion 1100-1 [11114647.001]
  • [Cites] BMC Cancer. 2008;8:21 [18215290.001]
  • [Cites] J Biomed Opt. 2008 Sep-Oct;13(5):054001 [19021381.001]
  • [Cites] J Biomed Opt. 2005 Sep-Oct;10(5):051602 [16292950.001]
  • [Cites] J Invest Dermatol. 1999 Sep;113(3):293-303 [10469324.001]
  • [Cites] Clin Dermatol. 2003 Sep-Oct;21(5):359-69 [14678715.001]
  • [Cites] Dermatol Surg. 2003 Aug;29(8):839-46 [12859385.001]
  • [Cites] J Biomed Opt. 2007 Sep-Oct;12(5):051901 [17994884.001]
  • (PMID = 19650910.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Other-IDs] NLM/ PMC3087331
  •  go-up   go-down


79. Tse GM, Tan PH, Lui PC, Gilks CB, Poon CS, Ma TK, Law BK, Lam WW: The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. J Clin Pathol; 2007 Mar;60(3):315-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast.
  • The evaluation of myoepithelial cells can be helpful, with benign papilloma showing a continuous myoepithelial cell layer, which becomes attenuated or absent in malignant papillary lesions.
  • METHODS: A large series of 100 papillomas (28 papillomas with florid epithelial hyperplasia) and 68 papillary carcinomas (9 invasive, 44 in situ, and 15 ductal carcinomas in situ (DCIS) involving papillomas) of the breast were stained for myoepithelial cells by immunohistochemistry using antibodies to smooth-muscle actin (SMA), p63, CD10 and cytokeratin (CK) 14.
  • CK14 and p63 may be used as an adjunct in assessing difficult papillary lesions of the breast.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Breast Neoplasms / metabolism
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Aged, 80 and over. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. DNA-Binding Proteins / metabolism. Diagnosis, Differential. Female. Humans. Keratin-14 / metabolism. Middle Aged. Neoplasm Proteins / metabolism. Neprilysin / metabolism. Papilloma / metabolism. Papilloma / pathology. Papilloma, Intraductal / metabolism. Papilloma, Intraductal / pathology. Trans-Activators / metabolism. Transcription Factors. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Nov;52(11):862-4 [10690183.001]
  • [Cites] Pathology. 2006 Feb;38(1):16-20 [16484002.001]
  • [Cites] Diagn Cytopathol. 2000 Sep;23(3):151-5 [10945900.001]
  • [Cites] Histopathology. 2000 Sep;37(3):232-40 [10971699.001]
  • [Cites] Mod Pathol. 2001 May;14(5):465-71 [11353058.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1054-60 [11474290.001]
  • [Cites] Histopathology. 2001 Sep;39(3):273-8 [11532038.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):494-501 [11839669.001]
  • [Cites] Mod Pathol. 2002 Apr;15(4):397-405 [11950913.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):101-8 [12109843.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):936-9 [12461063.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):336-40 [12653579.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):20-3 [12704442.001]
  • [Cites] Cancer. 2003 Jun 25;99(3):172-9 [12811858.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):165-71 [14631369.001]
  • [Cites] Histol Histopathol. 2004 Apr;19(2):465-71 [15024707.001]
  • [Cites] Semin Diagn Pathol. 2004 Feb;21(1):32-41 [15074557.001]
  • [Cites] J Pathol. 2004 Jun;203(2):661-71 [15141381.001]
  • [Cites] Am J Clin Pathol. 2004 Aug;122(2):217-21 [15323138.001]
  • [Cites] Am J Clin Pathol. 2004 Sep;122(3):440-3 [15362376.001]
  • [Cites] Am J Surg Pathol. 2004 Nov;28(11):1506-12 [15489655.001]
  • [Cites] Clin Immunol Immunopathol. 1975 May;4(1):67-84 [1092499.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):122-33 [7195300.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):451-61 [6351647.001]
  • [Cites] Mod Pathol. 1989 Nov;2(6):569-76 [2479944.001]
  • [Cites] Am J Pathol. 1991 Mar;138(3):751-63 [1705754.001]
  • [Cites] Histopathology. 1991 Jun;18(6):517-22 [1715306.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1992;421(4):315-22 [1384226.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):708-13 [10227293.001]
  • [Cites] Nature. 1999 Apr 22;398(6729):714-8 [10227294.001]
  • [Cites] Ann Surg. 1951 Jan;133(1):18-36 [14800254.001]
  • [Cites] Cancer. 1962 May-Jun;15:444-55 [14459407.001]
  • [Cites] Breast J. 2005 Jan-Feb;11(1):2-8 [15647071.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):185-9 [15677540.001]
  • [Cites] Histopathology. 2005 Mar;46(3):320-7 [15720418.001]
  • [Cites] Am J Clin Pathol. 2005 Jan;123(1):36-44 [15762278.001]
  • [Cites] Am J Surg Pathol. 2005 May;29(5):625-32 [15832086.001]
  • [Cites] J Clin Pathol. 2005 Nov;58(11):1185-8 [16254109.001]
  • [Cites] Am J Clin Pathol. 2000 Mar;113(3):374-82 [10705818.001]
  • (PMID = 16698948.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Keratin-14; 0 / Neoplasm Proteins; 0 / TP63 protein, human; 0 / Trans-Activators; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; EC 3.4.24.11 / Neprilysin
  • [Other-IDs] NLM/ PMC1860581
  •  go-up   go-down


80. Volgger B, Kurz K, Zöschg K, Theurl I, Ciresa-König A, Marth C, Weiss G: Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer. Anticancer Res; 2010 Sep;30(9):3721-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of erythropoetin receptor expression in tumour tissue for the clinical course of breast cancer.
  • BACKGROUND: Adverse outcomes in breast cancer patients treated with recombinant human erythropoietin (rhEpo) have been linked to the expression of Epo-receptors (EpoR) in cancer cells, although limited data on the clinical significance of these observations are available.
  • PATIENTS AND METHODS: Tissue samples from 107 patients with breast cancer who did not receive rhEpo and from 12 patients with benign lesions were retrospectively analysed for EpoR expression by RT-PCR and Western blot, and the results were correlated to clinical and demographic data.
  • [MeSH-major] Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Receptors, Erythropoietin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Erythropoietin / adverse effects. Female. Humans. Kaplan-Meier Estimate. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Recombinant Proteins. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20944160.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Receptors, Erythropoietin; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin
  •  go-up   go-down


81. Corben AD, Nehhozina T, Garg K, Vallejo CE, Brogi E: Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma. Am J Surg Pathol; 2010 Aug;34(8):1211-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endosalpingiosis in axillary lymph nodes: a possible pitfall in the staging of patients with breast carcinoma.
  • The occurrence of benign epithelial inclusions in lymph nodes is well documented and can sometimes mimic metastatic carcinoma.
  • Benign müllerian inclusions, such as endometriosis and endosalpingiosis, are common in pelvic and para-aortic lymph nodes, but their presence in supradiaphragmatic lymph nodes is a rare event.
  • We report our experience with 3 patients found to have endosalpingiosis in axillary sentinel lymph nodes obtained for staging of breast carcinoma.
  • Endosalpingiosis had been misinterpreted as metastatic carcinoma at another hospital in 1 of the 3 patients, with subsequent dissection of 19 additional benign axillary lymph nodes.
  • Morphologic identification of ciliated cells and "peg" cells is most helpful to recognize this benign inclusion, and positive immunoreactivity for WT1 and/or PAX8 can be used to support the diagnosis.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Diagnostic Errors / prevention & control. Epithelial Cells / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Cilia. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Paired Box Transcription Factors / analysis. Predictive Value of Tests. Sentinel Lymph Node Biopsy. Unnecessary Procedures. WT1 Proteins / analysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20631604.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX8 protein, human; 0 / Paired Box Transcription Factors; 0 / WT1 Proteins
  • [Number-of-references] 32
  •  go-up   go-down


82. Dragoumis DM, Assimaki AS, Tsiftsoglou AP: Solid variant of a pure intracystic papillary carcinoma of the breast: case report. Eur J Gynaecol Oncol; 2008;29(5):545-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid variant of a pure intracystic papillary carcinoma of the breast: case report.
  • Intracystic papillary carcinoma (IPC) of the breast is an uncommon malignant breast neoplasm and usually occurs in advanced age.
  • It is characterized by a more benign behavior and a subsequent higher survival rate.
  • We describe such a case of a 58-year-old female, who displayed a gradually growing tumor of the right breast.
  • Mammography, breast ultrasonography and fine needle aspiration cytology failed to obtain a definite diagnosis.
  • Based on the preoperative clinical identification of right axillary lymphadenopathy, the patient eventually underwent segmental resection of the right breast and right axillary nodal dissection.
  • As regards the histological findings, the neoplasm corresponded to a pure intracystic papillary carcinoma of the solid variant.
  • IPC represents a breast tumor with papillary differentiation growing inside a cyst, and excisional biopsy is often necessary to confirm the disease.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Papillary / pathology
  • [MeSH-minor] Breast Cyst / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19051833.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


83. Lee JM, Georgian-Smith D, Gazelle GS, Halpern EF, Rafferty EA, Moore RH, Yeh ED, D'Alessandro HA, Hitt RA, Kopans DB: Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology; 2008 Aug;248(2):398-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions.
  • RESULTS: Of 554 mammograms (265 TRAM flap reconstructions), 546 (98.6%) had negative results (Breast Imaging Reporting and Data System category 1 or 2).
  • Eight (1.4%) had positive test results (Breast Imaging Reporting and Data System category 0, 3, 4, or 5).
  • All suspicious lesions underwent biopsy and had benign pathologic results.
  • No interval breast cancers were identified.
  • The detection rate for nonpalpable recurrent breast cancer was 0% (exact 95% confidence interval: 0.0%, 1.4%).
  • CONCLUSION: Routine screening mammography of TRAM flap reconstructions has a very low detection rate for nonpalpable recurrent breast cancer.
  • Decision analysis indicates that screening such women is less effective than screening asymptomatic women in their 40s for primary breast cancer.
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / surgery. Mammaplasty. Neoplasm Recurrence, Local / radiography. Rectus Abdominis / transplantation. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Decision Support Techniques. Female. Humans. Mammography. Mastectomy. Middle Aged. Retrospective Studies. Treatment Outcome


84. Ishikawa T, Hamaguchi Y, Tanabe M, Momiyama N, Chishima T, Nakatani Y, Nozawa A, Sasaki T, Kitamura H, Shimada H: False-positive and false-negative cases of fine-needle aspiration cytology for palpable breast lesions. Breast Cancer; 2007;14(4):388-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] False-positive and false-negative cases of fine-needle aspiration cytology for palpable breast lesions.
  • BACKGROUND: Fine-needle aspiration cytology (FNA) is less traumatic and technically easy to apply to small breast tumors.
  • METHODS: A total of 382 cases of palpable breast lesions that had undergone fine needle aspiration and histopathologic diagnosis were reviewed with an emphasis on the rate of false positive diagnoses in benign breast lesions.
  • RESULTS: A diagnosis of " malignant " was made in 98 of the 382 specimens (25.6%).
  • CONCLUSION: Palpable breast tumors can be definitively diagnosed based on a combination of physical examination, radiological studies and FNA, when the radiological studies concur with the diagnosis by FNA.
  • [MeSH-major] Biopsy, Needle. Breast Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adult. Cytodiagnosis. False Negative Reactions. False Positive Reactions. Female. Humans. Neoplasm Invasiveness. Neoplasms, Ductal, Lobular, and Medullary / parasitology. Predictive Value of Tests. Prognosis. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986804.001).
  • [ISSN] 1880-4233
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Tokés AM, Kulka J, Paku S, Szik A, Páska C, Novák PK, Szilák L, Kiss A, Bögi K, Schaff Z: Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res; 2005;7(2):R296-305
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Claudin-1, -3 and -4 proteins and mRNA expression in benign and malignant breast lesions: a research study.
  • INTRODUCTION: We compared levels of protein and mRNA expression of three members of the claudin (CLDN) family in malignant breast tumours and benign lesions.
  • METHODS: Altogether, 56 sections from 52 surgically resected breast specimens were analyzed for CLDN1, CLDN3 and CLDN4 expression by immunohistochemistry. mRNA was also analyzed using real-time PCR in 17 of the 52 cases.
  • However, CLDN4 was highly positive in normal epithelial cells and was decreased or absent in 17 out of 21 ductal carcinoma grade 1, in special types of breast carcinoma (mucinous, papillary, tubular) and in areas of apocrine metaplasia.
  • CONCLUSIONS: The significant loss of CLDN1 protein in breast cancer cells suggests that CLDN1 may play a role in invasion and metastasis.
  • [MeSH-major] Breast Diseases / genetics. Breast Neoplasms / genetics. Membrane Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Differentiation. Claudin-1. Claudin-3. Claudin-4. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Messenger / analysis. RNA, Messenger / biosynthesis. Tight Junctions

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cell Biol. 1999 Dec;78(12):849-55 [10669103.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):48350-5 [11602598.001]
  • [Cites] Gastroenterology. 2001 Feb;120(2):411-22 [11159882.001]
  • [Cites] J Cell Biol. 2002 Mar 18;156(6):1099-111 [11889141.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):60-8 [11920682.001]
  • [Cites] Oncol Res. 2001;12(11-12):469-76 [11939410.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):e36 [11972351.001]
  • [Cites] Prog Biophys Mol Biol. 2003 Jan;81(1):1-44 [12475568.001]
  • [Cites] Oncogene. 2003 Apr 3;22(13):2021-33 [12673207.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):683-9 [12736707.001]
  • [Cites] Am J Respir Cell Mol Biol. 2003 Jul;29(1):62-70 [12600828.001]
  • [Cites] Arch Androl. 2003 Jul-Aug;49(4):271-9 [12851029.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2567-75 [12855632.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6265-71 [14559813.001]
  • [Cites] J Cell Sci. 1979 Feb;35:393-402 [422677.001]
  • [Cites] FEBS Lett. 1987 Sep 14;221(2):359-64 [3114004.001]
  • [Cites] Histopathology. 1991 Nov;19(5):403-10 [1757079.001]
  • [Cites] J Cell Physiol. 1992 Jul;152(1):35-47 [1618921.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):397-408 [9548718.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1539-50 [9647647.001]
  • [Cites] J Cell Biol. 1998 Oct 19;143(2):391-401 [9786950.001]
  • [Cites] Gene. 1999 Jan 21;226(2):285-95 [9931503.001]
  • [Cites] Trends Cell Biol. 1999 Jul;9(7):268-73 [10370242.001]
  • [Cites] Carcinogenesis. 1999 Aug;20(8):1425-31 [10426787.001]
  • [Cites] Curr Biol. 1999 Sep 23;9(18):1035-8 [10508613.001]
  • [Cites] J Cell Biol. 1999 Oct 4;147(1):195-204 [10508866.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2000 Aug;279(2):G250-4 [10915631.001]
  • [Cites] Hum Genet. 2000 Sep;107(3):249-56 [11071387.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6281-7 [11103784.001]
  • [Cites] Endocrinology. 2001 Feb;142(2):854-63 [11159859.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1319-27 [11375422.001]
  • [Cites] Clin Chem Lab Med. 2000 Feb;38(2):171-7 [10834406.001]
  • (PMID = 15743508.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Membrane Proteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC1064136
  •  go-up   go-down


86. Rozenchan PB, Carraro DM, Brentani H, de Carvalho Mota LD, Bastos EP, e Ferreira EN, Torres CH, Katayama ML, Roela RA, Lyra EC, Soares FA, Folgueira MA, Góes JC, Brentani MM: Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts. Int J Cancer; 2009 Dec 15;125(12):2767-77
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reciprocal changes in gene expression profiles of cocultured breast epithelial cells and primary fibroblasts.
  • The importance of epithelial-stroma interaction in normal breast development and tumor progression has been recognized.
  • To identify genes that were regulated by these reciprocal interactions, we cocultured a nonmalignant (MCF10A) and a breast cancer derived (MDA-MB231) basal cell lines, with fibroblasts isolated from breast benign-disease adjacent tissues (NAF) or with carcinoma-associated fibroblasts (CAF), in a transwell system.
  • Our data indicate that interactions between breast fibroblasts and basal epithelial cells resulted in alterations in the genomic profiles of both cell types which may help to clarify some aspects of this heterotypic signaling.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Epithelial Cells / metabolism. Fibroblasts / metabolism. Gene Expression Profiling. Neoplasm Proteins / genetics
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Breast / cytology. Cell Proliferation. Coculture Techniques. Female. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 UICC.
  • (PMID = 19530251.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


87. Paulino AC, Fowler BZ: Secondary neoplasms after radiotherapy for a childhood solid tumor. Pediatr Hematol Oncol; 2005 Mar;22(2):89-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary neoplasms after radiotherapy for a childhood solid tumor.
  • This study was conducted to determine the outcome of patients who develop a second neoplasm after radiotherapy (RT) for a childhood solid tumor.
  • From 1956 to 1998, 429 children with a malignant solid tumor were treated at a single radiation oncology facility.
  • The medical records and radiotherapy charts were reviewed to determine if the patient developed a secondary neoplasm after treatment for malignancy.
  • Twenty-three (5.4%) patients developed a secondary neoplasm.
  • There were 14 malignant neoplasms in 13 (3.0%) and 14 benign neoplasms in 11 patients (2.6%).
  • The types of initial solid tumors treated with RT were Ewing sarcoma in 6, Wilms tumor in 6, medulloblastoma in 5, neuroblastoma in 3, and other in 3.
  • For the 14 malignant neoplasms, the median time interval from initial tumor to second malignancy was 10.1 years.
  • The 14 second malignant neoplasms (SMN) were osteosarcoma in 3, breast carcinoma in 2, melanoma in 2, malignant fibrous histiocytoma in 1, dermatofibrosarcoma in 1, leiomyosarcoma in 1, mucoepidermoid carcinoma in 1, colon cancer in 1, chronic myelogenous leukemia in 1, and basal cell carcinoma in 1.
  • The 5- and 10-year overall survival rate after diagnosis of an SMN was 69.2%; it was 70% for children with a SMN at the edge or inside the RT field and 66.7% for those outside of the RT field.
  • The 14 benign neoplasms appeared at a median time of 16.9 years and included cervical intraepithelial neoplasia in 3, osteochondroma in 3, thyroid adenoma in 1, duodenal adenoma in 1, lipoma in 1, cherry angioma in 1, uterine leiomyoma in 1, ovarian cystadenofibroma in 1, and giant cell tumor in 1.
  • Only 5 (36%) of the 14 benign tumors occurred in the RT field, with osteochondroma being the most common.
  • More than two-thirds of children with a radiation-induced malignancy are alive 10 years after the diagnosis of a SMN.
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Male. Radiation Dosage. Retrospective Studies. Survival Rate


88. Abdalla HM, Sakr MA: Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast. J Egypt Natl Canc Inst; 2006 Jun;18(2):125-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive factors of local recurrence and survival following primary surgical treatment of phyllodes tumors of the breast.
  • BACKGROUND AND PURPOSE: The phyllodes tumor is characterized by its tendency to recur locally and occasionally to metastasize.
  • The aim of this study was to determine parameters that influence outcome in this uncommon neoplasm.
  • The tumor size ranged from 2.5 to 24 cm, with a median of 11 cm.
  • Based on the criteria proposed by WHO, 31 cases were benign tumors (39.2%), 27 borderline tumors (34.2%), and 21 malignant tumors (26.6%).
  • Following local excision, the local recurrence rates were 14.3%, 50%, and 75% in patients with benign, borderline, and malignant tumors; respectively, while after wide local excision the local recurrence rates were 0%, 36.3% and 40%; respectively.
  • Whereas, 0%, 8.3%, and 8.3% of patients with benign, borderline and malignant tumors; respectively, locally recurred after mastectomy.
  • Distant metastases developed in 3.2%, 11.1%, and in 28.6% of patients with benign, borderline and malignant tumors; respectively.
  • The 5-year survival with no evidence of disease was 90% for the patients with benign tumors compared to 69% for borderline and 61% for malignant PTs (p= 0.02).
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Phyllodes Tumor / pathology
  • [MeSH-minor] Adolescent. Aged. Female. Humans. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17496937.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


89. Yilmaz MH, Ozguroglu M, Mert D, Turna H, Demir G, Adaletli I, Ulus S, Halac M, Kanberoğlu K: Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study. Med Oncol; 2008;25(3):257-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of magnetic resonance imaging and scintigraphy in patients with metastatic breast cancer of the axial skeleton: a comparative study.
  • PATIENTS AND METHODS: A total of 59 patients (58 women and 1 man, age range 28-83 years, mean age 53.0 years) with histopathologically proven breast cancer during a 15-month period (between April 2003 and January 2004) were included in the study.
  • Four lesions detected by MRI were classified as of uncertain origin (grade 2) and 36 lesions were regarded as definitely benign (grade 1).
  • A total of 29 lesions were considered as of uncertain origin (grade 2), and 26 lesions were regarded as definitely benign (grade 1).
  • About five lesions were graded as grade 2 in scintigraphy, while MRI graded them as degeneration or benign compression (Grade 1).
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diphosphonates. Female. Humans. Male. Middle Aged. Neoplasm Staging. Organotechnetium Compounds. Predictive Value of Tests. Radiography. Radionuclide Imaging. Sensitivity and Specificity. Whole Body Imaging

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1989 Jul-Aug;13(4):598-602 [2745777.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 [10200775.001]
  • [Cites] Radiology. 1993 Jul;188(1):249-52 [8511306.001]
  • [Cites] Skeletal Radiol. 1986;15(1):1-9 [3941915.001]
  • [Cites] AJR Am J Roentgenol. 1986 Feb;146(2):353-8 [3484586.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1595-607 [9362427.001]
  • [Cites] Radiol Clin North Am. 1987 Nov;25(6):1155-70 [3671711.001]
  • [Cites] Clin Orthop Relat Res. 1982 Sep;(169):38-43 [6179682.001]
  • [Cites] Clin Nucl Med. 1989 Oct;14 (10 ):742-9 [2805524.001]
  • [Cites] Blood. 1991 Aug 1;78(3):728-38 [1859885.001]
  • [Cites] Cancer. 1987 Nov 15;60(10 ):2524-31 [3664434.001]
  • [Cites] Clin Orthop Relat Res. 1986 Sep;(210):18-30 [3757360.001]
  • [Cites] AJR Am J Roentgenol. 1990 Nov;155(5):1043-8 [2120933.001]
  • [Cites] Clin Radiol. 1976 Jan;27(1):9-15 [177243.001]
  • [Cites] Semin Nucl Med. 1995 Apr;25(2):76-91 [7597422.001]
  • [Cites] Skeletal Radiol. 1990;19(2):113-6 [2321040.001]
  • [Cites] Spine (Phila Pa 1976). 1996 Oct 1;21(19):2243-50 [8902969.001]
  • [Cites] Magn Reson Imaging. 1994;12 (6):829-35 [7968282.001]
  • [Cites] Eur J Radiol. 2001 Oct;40(1):16-23 [11673003.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Jul;18(7):629-36 [6889965.001]
  • [Cites] Magn Reson Imaging. 1991;9(3):349-55 [1881253.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1415-21 [8021732.001]
  • [Cites] Nucl Med Commun. 1992 Jun;13(6):429-31 [1407869.001]
  • [Cites] Cancer. 1986 Jul 1;58(1):178-82 [2423224.001]
  • [Cites] AJR Am J Roentgenol. 1997 Dec;169(6):1655-61 [9393186.001]
  • [Cites] Am J Med. 1986 Sep;81(3):381-6 [2428242.001]
  • [Cites] J Comput Assist Tomogr. 1989 Jul-Aug;13(4):717-9 [2745798.001]
  • [Cites] Radiology. 1989 Jul;172(1):215-8 [2740506.001]
  • [Cites] Eur Radiol. 2004 Dec;14 (12 ):2297-302 [15243716.001]
  • [Cites] Radiol Clin North Am. 1990 Mar;28(2):471-83 [2408106.001]
  • [Cites] Magn Reson Imaging. 1992;10(2):169-76 [1564986.001]
  • [Cites] Semin Oncol. 1991 Apr;18(2):158-69 [2014400.001]
  • [Cites] Eur J Nucl Med. 1993 Nov;20(11):1063-9 [8287874.001]
  • [Cites] J Comput Assist Tomogr. 1999 Jan-Feb;23 (1):123-9 [10050822.001]
  • [Cites] Br J Cancer. 1973 Apr;27(4):336-40 [4701705.001]
  • [Cites] Lancet. 1983 Sep 10;2(8350):613-6 [6136757.001]
  • [Cites] Br J Urol. 1995 Jan;75(1):54-8 [7850297.001]
  • [Cites] AJR Am J Roentgenol. 1977 Dec;129(6):1095-6 [74204.001]
  • [Cites] J Nucl Med. 1996 Jun;37(6):975-8 [8683325.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12 ):2191-8 [8254410.001]
  • (PMID = 18040900.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Organotechnetium Compounds; 0 / technetium 99m methylene bisphosphonate
  •  go-up   go-down


90. Brenn T, Fletcher CD: Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol; 2005 Aug;29(8):983-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical post-radiation vascular lesions (AVLs) with a benign course have been described recently, but few cases with limited follow-up have been studied so far.
  • All patients were female with a median age of 59 years (range, 36-90 years).
  • Reasons for radiation included breast carcinoma (35 cases) and a variety of other lesions (mainly malignant disease).
  • All patients with systemic relapse had an initial diagnosis of angiosarcoma.
  • No adverse outcome has been observed so far in this more benign subset of cases, but longer-term follow-up is necessary.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms / radiotherapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasms / radiotherapy. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16006792.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Kurihara T, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Tsuji S, Ishii K, Ikeuchi N, Tsuchida A, Kasuya K, Kawai T, Sakai Y, Moriyasu F: Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result. J Hepatobiliary Pancreat Surg; 2008;15(2):189-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of circulating tumor cells in patients with pancreatic cancer: a preliminary result.
  • BACKGROUND/PURPOSE: It has been reported that circulating tumor cells (CTCs) can be used to predict survival in metastatic breast cancer.
  • CTC was negative in 15 patients with PC (stage II, 1; stage III, 1; stage IVa, 7; and stage IVb, 6) and in the subjects with benign conditions.
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392713.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


92. Calcaterra V, Coscia DR, Sgarell A, Burroni B, Podetta M, Andorno A, Ferrari A, Larizza D: Recurrence of giant juvenile breast fibroadenoma in a girl with Turner's syndrome. J Pediatr Endocrinol Metab; 2009 Mar;22(3):281-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence of giant juvenile breast fibroadenoma in a girl with Turner's syndrome.
  • Pathological breast conditions are rare in childhood and adolescence.
  • The spectrum of breast disease in pediatric patients is different from that in adults and most lesions are benign.
  • Fibroadenomas are the most common type of breast tumor in adolescent girls and young women.
  • We report here a case of recurrent juvenile giant breast fibroadenoma in a girl with Turner's syndrome.
  • [MeSH-major] Breast Neoplasms / pathology. Fibroadenoma / pathology. Neoplasm Recurrence, Local / pathology. Turner Syndrome / pathology
  • [MeSH-minor] Child. Female. Humans. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Turner Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19492586.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Shin SJ, Simpson PT, Da Silva L, Jayanthan J, Reid L, Lakhani SR, Rosen PP: Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma. Am J Surg Pathol; 2009 Apr;33(4):496-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microglandular adenosis (MGA) is an uncommon, benign breast lesion that is characterized by a proliferation of small uniform, round glands lined by a single layer of epithelial cells around open lumina with haphazard infiltrative growth in fibrous and fatty breast tissue.
  • Such widespread genetic changes, together with recurrent loss of 5q and gain of 8q were reminiscent of those reported specifically for basal-like, estrogen receptor-negative, and BRCA1-associated breast tumors.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma in Situ / pathology. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / pathology. Chromosome Aberrations. Fibrocystic Breast Disease / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Comparative Genomic Hybridization. DNA, Neoplasm / analysis. Disease Progression. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Karyotyping. Microdissection. Middle Aged

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047897.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


94. Roncella S, Ferro P, Bacigalupo B, Dessanti P, Pronzato P, Franceschini MC, Pratticò L, Carletti AM, Canessa PA, Fontana V, Fais F, Pistillo MP, Fedeli F: Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions. Diagn Mol Pathol; 2008 Mar;17(1):28-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of RT-PCR detection of human mammaglobin for the diagnosis of breast cancer derived pleural effusions.
  • The present study investigates the diagnostic significance of human mammaglobin (hMAM) mRNA expression in pleural effusions (PE) from breast cancer (BC) patients.
  • Two hundred and fifty PE samples, including 32 from patients who had diagnosis of BC, 116 from patients with other cancers, and 102 from patients with benign diseases, were subjected to nested reverse-transcription polymerase chain reaction (RT-PCR) for hMAM, and the results were compared with conventional cytology. hMAM was found expressed in 76/250 (30.4%) total PE and in 23/28 (sensitivity of 82.1%) of the PE subgroup owing to metastasis from BC.
  • The specificity for hMAM detection method was 75.7%, whereas accuracy, positive predictive value, and negative predictive value were 76.4%, 30.3%, and 97.1%, respectively. hMAM was also detected in 46/116 (39.6%) PE specimens from other types of cancer and in 7/102 (6.8%) from benign diseases.
  • [MeSH-major] Breast Neoplasms / diagnosis. Carcinoma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion, Malignant / diagnosis. Reverse Transcriptase Polymerase Chain Reaction. Uteroglobin / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation, Neoplastic. Humans. Mammaglobin A. Middle Aged. RNA, Messenger / metabolism. Sensitivity and Specificity. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303409.001).
  • [ISSN] 1052-9551
  • [Journal-full-title] Diagnostic molecular pathology : the American journal of surgical pathology, part B
  • [ISO-abbreviation] Diagn. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


95. Bacci G, Ferrari C, Longhi A, Ferrari S, Forni C, Bacchini P, Palmerini E, Briccoli A, Pignotti E, Balladelli A, Picci P: Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy. J Pediatr Hematol Oncol; 2006 Dec;28(12):774-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second malignant neoplasm in patients with osteosarcoma of the extremities treated with adjuvant and neoadjuvant chemotherapy.
  • Twenty-six patients (2.15%) developed a second malignant neoplasm at a median of 7.6 years (1 to 25 y) after primary osteosarcoma treatment.
  • Second neoplasms were leukemia (10), breast (7), lung (2), kidney (2), central nervous system cancer (2), soft tissue (1), parotid (1), and colon (1).
  • The rate of second neoplasms was significantly higher in female patients, and the latent period shorter in hematologic tumors compared with solid tumors.
  • The rate of second malignancies observed in the osteosarcoma group was significantly higher than that observed in the control group of 1160 patients with benign tumors treated in the same period at our Institute (2.2% vs. 0.8%, P<0.009).
  • Our study showed that the risk of second neoplasm within 15 years increased and then leveled off and that although secondary solid tumors could be explained as unrelated cases, leukemias seem to be over represented.
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant / methods. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Incidence. Infant. Male. Neoplasms / drug therapy. Neoplasms / epidemiology. Retrospective Studies. Risk Factors. Sex Factors. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17164644.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


96. Fang Y, Gao JD, Tian YT, Xie YQ, Zhen S: [Analysis of the treatment and prognosis of recurrent breast phyllodes tumor]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):72-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of the treatment and prognosis of recurrent breast phyllodes tumor].
  • OBJECTIVE: To explore the methods of diagnosis, treatment and prognosis for patients with recurrent breast phyllodes tumor.
  • The primary breast phyllodes tumor was > or = 5 cm in 10 cases with a recurrence rate of 60.0% (6/10 cases); < 5 cm in 16 cases with a recurrence rate of 31.3% 5/16 cases).
  • After surgical removal of the breast primary tumor, the recurrent tumor was > or = 5 cm in 14 cases with a re-recurrence rate of 35.7% (5/14 cases); < 5 cm was in 12 cases with are-recurrence rate of 50.0% (6/12 cases).
  • There was no statistically significant relationship between the (primary and reccurent) tumor size and recurrence rate (P = 0.094, P = 0.383) or prognosis (P = 0.142, P = 0.486).
  • The benign or malignant nature of the breast phyllodes tumor was significantly correlated with the rate of local re-recurrence (P = 0.046) and prognosis (P = 0.028).
  • CONCLUSION: The benign or malignant nature of the breast phyllodes tumor is significantly correlated with the local re-recurrence and prognosis, while the size of the primary breast phyllodes tumor has no significant effect on either re-recrruence or prognosis.
  • The first rescue operation is most important in the treatment of recurrent breast phyllodes tumor.
  • Active surgical treatment can still effectively save the life of the patients with a local re-recurrent tumor.
  • [MeSH-major] Breast Neoplasms / surgery. Mastectomy / methods. Neoplasm Recurrence, Local / surgery. Phyllodes Tumor / surgery
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Child. Female. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Phyllodes Tumor.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538877.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


97. Lorenzen J, Wedel AK, Lisboa BW, Löning T, Adam G: [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome]. Rofo; 2005 Nov;177(11):1545-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic mammography and sonography: concordance of the breast imaging reporting assessments and final clinical outcome].
  • Final clinical outcome (Histology: 554; follow-up: 78) was ascertained in each case and concordance of BI-RADS-categories for mammography and sonography and final diagnosis were analysed.
  • RESULTS: Final diagnosis yielded 230 benign lesions (36 %) and 402 cancers (64 %).
  • [MeSH-major] Breast Neoplasms / radiography. Breast Neoplasms / ultrasonography. Mammography. Ultrasonography, Mammary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Breast / pathology. Data Interpretation, Statistical. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Outcome and Process Assessment (Health Care). Quality Assurance, Health Care. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16302136.001).
  • [ISSN] 1438-9029
  • [Journal-full-title] RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin
  • [ISO-abbreviation] Rofo
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


98. Kakagia D, Fragia K, Grekou A, Tsoutsos D: Reduction mammaplasty specimens and occult breast carcinomas. Eur J Surg Oncol; 2005 Feb;31(1):19-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduction mammaplasty specimens and occult breast carcinomas.
  • Other benign changes were identified in totally 133 patients.
  • [MeSH-major] Breast Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Ductal, Breast / epidemiology. Carcinoma, Lobular / epidemiology. Mammaplasty
  • [MeSH-minor] Adult. Female. Humans. Mastectomy. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2005 Sep;31(7):806 [15923102.001]
  • (PMID = 15642421.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Tok EC, Ertunc D, Tataroglu C, Yazici G, Kanat H, Dilek S: Clinicopathologic study of the putative precursor lesions of epithelial ovarian cancer in low-risk women. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):501-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Possible precursor lesions for epithelial ovarian cancer (EOC) have been defined in the ovaries of women with contralateral EOC, with breast cancer susceptibility gene (BRCA)-1 mutations, or with positive family history.
  • The study group consisted of 184 women who were operated for benign gynecological conditions.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cohort Studies. Contraceptives, Oral. Female. Humans. Menopause. Middle Aged. Neoplasm Invasiveness. Ovariectomy. Phenotype. Precancerous Conditions / pathology. Reproduction / physiology. Risk Factors. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681718.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contraceptives, Oral
  •  go-up   go-down


100. Stucky CC, McLaughlin SA, Dueck AC, Gray RJ, Giurescu ME, Carpenter SG, Grimsby GM, Apsey HA, Pockaj BA: Does magnetic resonance imaging accurately predict residual disease in breast cancer? Am J Surg; 2009 Oct;198(4):547-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does magnetic resonance imaging accurately predict residual disease in breast cancer?
  • BACKGROUND: The accuracy of magnetic resonance imaging (MRI) in identifying residual disease after breast conservation therapy (BCT) is unclear.
  • Nine patients had false-positive MRI as seen by benign pathology findings.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Mastectomy, Segmental. Middle Aged. Predictive Value of Tests






Advertisement